# EDGAR Filing Document

**Accession Number:** 0000744452
**File Stem:** 0001410578-25-001814
**Filing Date:** 2025-8
**Character Count:** 150670
**Document Hash:** 48c538f3c1d5ac75ab3f30714f014a91
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001410578-25-001814.hdr.sgml**: 20250814

**ACCESSION NUMBER**: 0001410578-25-001814

**CONFORMED SUBMISSION TYPE**: 10-Q

**PUBLIC DOCUMENT COUNT**: 65

**CONFORMED PERIOD OF REPORT**: 20250630

**FILED AS OF DATE**: 20250814

**DATE AS OF CHANGE**: 20250814

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** APPLIED DNA SCIENCES INC
- **CENTRAL INDEX KEY:** 0000744452
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-TESTING LABORATORIES [8734]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 592262718
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 0930

**FILING VALUES:**
- **FORM TYPE:** 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-36745
- **FILM NUMBER:** 251219074

**BUSINESS ADDRESS:**
- **STREET 1:** 50 HEALTH SCIENCES DRIVE
- **CITY:** STONY BROOK
- **STATE:** NY
- **ZIP:** 11790
- **BUSINESS PHONE:** 631-240-8800

**MAIL ADDRESS:**
- **STREET 1:** 50 HEALTH SCIENCES DRIVE
- **CITY:** STONY BROOK
- **STATE:** NY
- **ZIP:** 11790

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** PROHEALTH MEDICAL TECHNOLOGIES INC
- **DATE OF NAME CHANGE:** 20010504

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** DCC ACQUISITION CORP
- **DATE OF NAME CHANGE:** 19990211

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** DATALINK CAPITAL CORP/TX/
- **DATE OF NAME CHANGE:** 19980306

?xml version='1.0' encoding='ASCII'? APPLIED DNA SCIENCES INC._June 30, 2025

[**Table of Contents**](#TOC)

------

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 10-Q**

☒ **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934** 

**For the quarterly period ended June 30, 2025**

**OR**

☐ **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the transition period from&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to**

**Commission File Number: 001-36745**

**Applied DNA Sciences, Inc.**

(Exact name of registrant as specified in its charter)

---

| | |
|:---|:---|
| **Delaware** | **59-2262718** |
| (State or other jurisdiction of | (I.R.S. Employer |
| incorporation or organization) | Identification No.) |
| **50 Health Sciences Drive** |  |
| **Stony Brook, New York** | **11790** |
| (Address of principal executive offices) | (Zip Code) |

---

**631-240-8800**

(Registrant's telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **TradingSymbol(s)** | **Name of each exchange on whichregistered** |
| Common Stock, $0.001 par value | APDN | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

☒ Yes&nbsp;&nbsp;&nbsp;&nbsp;☐&nbsp;&nbsp;&nbsp;&nbsp;No

Indicate by check mark whether the registrant has submitted electronically, every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

☒ Yes&nbsp;&nbsp;&nbsp;&nbsp;☐&nbsp;&nbsp;&nbsp;&nbsp;No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer ☐ Accelerated filer ☐ <br> Non-accelerated filer ☒ Smaller reporting company ☒ <br> Emerging Growth Company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

☐ Yes&nbsp;&nbsp;&nbsp;&nbsp;☒&nbsp;&nbsp;&nbsp;&nbsp;No

On August 12, 2025, the registrant had 1,291,465 shares of common stock outstanding.

------

[**Table of Contents**](#TOC)

**Applied DNA Sciences, Inc. and Subsidiaries**

Form 10-Q for the Quarterly Period Ended June 30, 2025

**Table of Contents**

---

| | |
|:---|:---|
|  | **Page** |
| [**PART I - FINANCIAL INFORMATION**](#PartIFinancialInformation_323894) |  |
| [Item 1 - Condensed Consolidated Financial Statements (unaudited)](#Item1FinancialStatements_322517) | 1 |
| [Item 2 - Management's Discussion and Analysis of Financial Condition and Results of Operations](#Item2ManagementsDiscussionandAnalysisofF) | 24 |
| [Item 3 - Quantitative and Qualitative Disclosures About Market Risk](#Item3QuantitativeandQualitativeDisclosur) | 34 |
| [Item 4 - Controls and Procedures](#Item4ControlsandProcedures_797675) | 35 |
| [**PART II - OTHER INFORMATION**](#PartIIOtherInformation_751745) |  |
| [Item 1 – Legal Proceedings](#Item1LegalProceedings_226160) | 36 |
| [Item 1A – Risk Factors](#Item1ARiskFactors_153545) | 36 |
| [Item 2 – Unregistered Sales of Equity Securities and Use of Proceeds](#Item2UnregisteredSalesofEquitySecurities) | 36 |
| [Item 3 – Defaults Upon Senior Securities](#Item3DefaultsUponSeniorSecurities_559120) | 36 |
| [Item 4 – Mine Safety Disclosures](#Item4MineSafetyDisclosures_527805) | 36 |
| [Item 5 – Other Information](#Item5OtherInformation_776657) | 36 |
| [Item 6 – Exhibits](#Item6Exhibits_305749) | 37 |

---

[**Table of Contents**](#TOC)

**Part I - Financial Information**

#### Item 1 - Financial Statements

#### APPLIED DNA SCIENCES, INC. AND SUBSIDIARIES

#### CONDENSED CONSOLIDATED BALANCE SHEETS

---

| | | |
|:---|:---|:---|
|  | **June 30,**  | **September 30,**  |
|  | **2025** | **2024** |
| **ASSETS** | **(unaudited)** |  |
| Current assets: |  |  |
| Cash and cash equivalents | $4727677 | $5852363 |
| Accounts receivable, net of allowance for credit losses of $80,423 and $75,000 at June 30, 2025 and September 30, 2024, respectively | 199047 | 328252 |
| Inventories | 338723 | 432725 |
| Prepaid expenses and other current assets | 338447 | 756185 |
| Current assets of discontinued operations | 25008 | 678146 |
| Total current assets | 5628902 | 8047671 |
| Property and equipment, net | 511203 | 458895 |
| Noncurrent assets of discontinued operations | 11264 | 94337 |
| Other assets: |  |  |
| Restricted cash | 750000 | 750000 |
| Intangible assets  | 2698975 | 2698975 |
| Operating right of use asset | 334402 | 739162 |
| Total assets | $9934746 | $12789040 |
| **LIABILITIES AND EQUITY** |  |  |
| Current liabilities: |  |  |
| Accounts payable and accrued liabilities  | $1564707 | $1737366 |
| Operating lease liability, current | 334403 | 545912 |
| Deferred revenue | 12285 | 58785 |
| Current liabilities of discontinued operations | 124565 | 56061 |
| Total current liabilities | 2035960 | 2398124 |
| Long term accrued liabilities | 31467 | 31467 |
| Deferred revenue, long term | 194000 | 194000 |
| Operating lease liability, long term |  | 193249 |
| Deferred tax liability, net | 684115 | 684115 |
| Warrants classified as a liability | 1160 | 320000 |
| Total liabilities | 2946702 | 3820955 |
| Commitments and contingencies (Note G) |  |  |
| Applied DNA Sciences, Inc. stockholders' equity: |  |  |
| Preferred stock, par value $0.001 per share; 10,000,000 shares authorized; -0- shares issued and outstanding as of June 30, 2025 and September 30, 2024 |  |  |
| Series A Preferred stock, par value $0.001 per share; 10,000,000 shares authorized; -0- issued and outstanding as of June 30, 2025 and September 30, 2024 |  |  |
| Series B Preferred stock, par value $0.001 per share; 10,000,000 shares authorized; -0- issued and outstanding as of June 30, 2025 and September 30, 2024 |  |  |
| Common stock, par value $0.001 per share; 200,000,000 shares authorized as of June 30, 2025 and September 30, 2024; 901,500 and 13,755 shares issued and outstanding as of June 30, 2025 and September 30, 2024, respectively | 902 | 14 |
| Additional paid in capital  | 381150267 | 318815358 |
| Accumulated deficit  | (373888601) | (309672755) |
| Applied DNA Sciences, Inc. stockholders' equity | 7262568 | 9142617 |
| Noncontrolling interest | (274524) | (174532) |
| Total equity | 6988044 | 8968085 |
| Total liabilities and equity | $9934746 | $12789040 |

---

See the accompanying notes to the unaudited condensed consolidated financial statements

[**Table of Contents**](#TOC)

#### APPLIED DNA SCIENCES, INC. AND SUBSIDIARIES

#### CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
**(Unaudited)**

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three months Ended June 30,** | **Three months Ended June 30,** | **Nine months Ended June 30,** | **Nine months Ended June 30,** |
|  | **2025** | **2024** | **2025** | **2024** |
| Revenues |  |  |  |  |
| &nbsp;&nbsp;Product revenues | $195262 | $246644 | $1239747 | $947086 |
| &nbsp;&nbsp;Service revenues | 109131 | 226145 | 697759 | 678777 |
| Total revenues | 304393 | 472789 | 1937506 | 1625863 |
| Cost of product revenues | 299263 | 230188 | 930619 | 853034 |
| Gross profit | 5130 | 242601 | 1006887 | 772829 |
| Operating expenses: |  |  |  |  |
| Selling, general and administrative | 2930627 | 2635863 | 8423602 | 8440919 |
| Research and development | 768563 | 913031 | 2632931 | 2762040 |
| Total operating expenses | 3699190 | 3548894 | 11056533 | 11202959 |
| LOSS FROM OPERATIONS | (3694060) | (3306293) | (10049646) | (10430130) |
| Interest income | 40267 | 29688 | 168762 | 33989 |
| Transaction costs allocated to warrant liabilities |  |  |  | (633198) |
| Unrealized gain on change in fair value of warrants classified as a liability | 6410 | 5160000 | 318840 | 9564000 |
| Unrealized loss on change in fair value of warrants classified as a liability - warrant modification |  |  |  | (394000) |
| Loss on issuance of warrants |  |  |  | (1633767) |
| Other expense, net | (531) | (103) | (23778) | (9060) |
| (Loss) income before provision for income taxes | (3647914) | 1883292 | (9585822) | (3502166) |
| Provision for income taxes |  |  |  |  |
| Net (loss) income from continuing operations  | $(3647914) | $1883292 | $(9585822) | $(3502166) |
| Net loss from discontinued operations, net of tax | (336195) | (33791) | (403120) | (272397) |
| NET (LOSS) INCOME  | $(3984109) | $1849501 | $(9988942) | $(3774563) |
| Less: Net loss attributable to noncontrolling interest | 38746 | 30295 | 99992 | 78785 |
| NET (LOSS) INCOME attributable to Applied DNA Sciences, Inc. | $(3945363) | $1879796 | $(9888950) | $(3695778) |
| Deemed dividend related to warrant modifications | (15500244) |  | (54326896) | (233087) |
| NET (LOSS) INCOME attributable to common stockholders | $(19445607) | $1879796 | $(64215846) | $(3928865) |
| Net (loss) income per share attributable to common stockholders-basic and diluted from continuing operations | $(33.41) | $1191.52 | $(255.14) | $(4862.32) |
| Net loss per share attributable to common stockholders-basic and diluted from discontinued operations | (0.59) | (21.04) | (1.61) | (362.23) |
| Net (loss) income per share attributable to common stockholders-basic and diluted  | $(34.00) | $1170.48 | $(256.75) | $(5224.55) |
| Weighted average shares outstanding- basic and diluted | 572018 | 1606 | 250107 | 752 |

---

See the accompanying notes to the unaudited condensed consolidated financial statements

[**Table of Contents**](#TOC)

#### APPLIED DNA SCIENCES, INC. AND SUBSIDIARIES

#### CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT)
**(Unaudited)**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Nine-Month Period ended June 30, 2024** | **Nine-Month Period ended June 30, 2024** | **Nine-Month Period ended June 30, 2024** | **Nine-Month Period ended June 30, 2024** | **Nine-Month Period ended June 30, 2024** | **Nine-Month Period ended June 30, 2024** |
|  | <br>**Common** <br>**Shares** | **Common** <br>**Stock** <br>**Amount** | **Additional** <br>**Paid in** <br>**Capital** | <br>**Accumulated** <br>**Deficit** | <br>**Noncontrolling**<br>**Interest** | <br><br>**Total** |
| Balance, October 1, 2023 | 911 | $1 | $307398305 | $(302447147) | $(78747) | $4872412 |
| Exercise of warrants, cashlessly |  |  |  |  |  |  |
| Stock based compensation expense |  |  | 340705 |  |  | 340705 |
| Common stock issued in ATM, net of offering costs | 6 |  | 45566 |  |  | 45566 |
| Deemed dividend - warrant repricing |  |  | 77757 | (77757) |  |  |
| Net Loss |  |  |  | (1105100) | (25181) | (1130281) |
| Balance December 31, 2023 | 917 | 1 | 307862333 | (303630004) | (103928) | 4128402 |
| Common stock issued in ATM, net of offering costs | 6 |  | 18831 |  |  | 18831 |
| Common stock issued in Registered direct offering, net of offering costs | 215 |  | 161 |  |  | 161 |
| Stock based compensation expense |  |  | 171004 |  |  | 171004 |
| Share issued upon restricted stock vesting | 19 |  |  |  |  |  |
| Deemed dividend - warrant repricing |  |  | 155330 | (155330) |  |  |
| Net loss |  |  |  | (4470474) | (23309) | (4493783) |
| Balance, March 31, 2024 | 1157 | $1 | $308207659 | $(308255808) | $(127237) | $(175385) |
| Common stock and pre-funded warrants issued in public offering, net of offering costs | 967 | 1 | 10525062 |  |  | 10525063 |
| Stock based compensation expense |  |  | 30336 |  |  | 30336 |
| Exercise of warrants | 11501 | 12 | 4928 |  |  | 4940 |
| Adjustment for reverse split | 113 |  |  |  |  |  |
| Net income |  |  |  | 1879796 | (30295) | 1849501 |
| Balance, June 30, 2024 | 13738 | $14 | $318767985 | $(306376012) | $(157532) | $12234455 |

---

[**Table of Contents**](#TOC)

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Nine-Month Period ended June 30, 2025** | **Nine-Month Period ended June 30, 2025** | **Nine-Month Period ended June 30, 2025** | **Nine-Month Period ended June 30, 2025** | **Nine-Month Period ended June 30, 2025** | **Nine-Month Period ended June 30, 2025** |
|  | <br>**Common**<br>**Shares** | **Common**<br>**Stock**<br>**Amount** | **Additional**<br>**Paid in**<br>**Capital** | <br>**Accumulated**<br>**Deficit** | <br>**Noncontrolling**<br>**Interest** | <br><br>**Total** |
| Balance, October 1, 2024 | 13755 | $14 | $318815358 | $(309672755) | $(174532) | $8968085 |
| Exercise of warrants | 3422 | 3 | 508597 |  |  | 508600 |
| Exercise of warrants, cashlessly | 27895 | 28 | (28) |  |  |  |
| Stock based compensation expense |  |  | 28973 |  |  | 28973 |
| Common stock and pre-funded warrants issued in registered direct offering, net of offering costs | 27083 | 27 | 5712673 |  |  | 5712700 |
| Deemed dividend - warrant repricing |  |  | 14907223 | (14907223) |  |  |
| Net Loss |  |  |  | (2639412) | (29301) | (2668713) |
| Balance December 31, 2024 | 72155 | 72 | 339972796 | (327219390) | (203833) | 12549645 |
| Exercise of warrants | 30003 | 30 | 984142 |  |  | 984172 |
| Exercise of warrants, cashlessly | 314845 | 315 | (315) |  |  |  |
| Stock based compensation expense |  |  | 26511 |  |  | 26511 |
| Deemed dividend - warrant repricing |  |  | 23919429 | (23919429) |  |  |
| Adjustment for reverse split | 5092 | 5 | (5) |  |  |  |
| Net loss |  |  |  | (3304175) | (31945) | (3336120) |
| Balance, March 31, 2025 | 422095 | $422 | $364902558 | $(354442994) | $(235778) | $10224208 |
| Exercise of warrants | 138557 | 139 | 722917 |  |  | 723056 |
| Exercise of warrants, cashlessly | 267236 | 267 | (267) |  |  |  |
| Stock based compensation expense |  |  | 24889 |  |  | 24889 |
| Deemed dividend - warrant repricing |  |  | 15500244 | (15500244) |  |  |
| Adjustment for reverse split | 73612 | 74 | (74) |  |  |  |
| Net loss |  |  |  | (3945363) | (38746) | (3984109) |
| Balance, June 30, 2025 | 901500 | $902 | $381150267 | $(373888601) | $(274524) | $6988044 |

---

See the accompanying notes to the unaudited condensed consolidated financial statements

[**Table of Contents**](#TOC)

#### APPLIED DNA SCIENCES, INC. AND SUBSIDIARIES

#### CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
**(Unaudited)**

---

| | | |
|:---|:---|:---|
|  | **Nine Months Ended June 30,**  | **Nine Months Ended June 30,**  |
|  | **2025** | **2024** |
| &nbsp;&nbsp;Cash flows from operating activities: |  |  |
| &nbsp;&nbsp;Net loss | $(9988942) | $(3774563) |
| &nbsp;&nbsp;Net loss from discontinued operations | (403120) | (272397) |
| &nbsp;&nbsp;Net loss from continuing operations | $(9585822) | $(3502166) |
| &nbsp;&nbsp;Adjustments to reconcile net loss from continuing operations to net cash used in operating activities from continuing operations: |  |  |
| &nbsp;&nbsp;Depreciation and amortization | 255601 | 388560 |
| &nbsp;&nbsp;Loss on write-off of property and equipment | 5212 |  |
| &nbsp;&nbsp;Unrealized gain on change in fair value of warrants classified as a liability | (318840) | (9564000) |
| &nbsp;&nbsp;Unrealized loss on change in fair value of warrants classified as a liability-warrant modification |  | 394000 |
| &nbsp;&nbsp;Transaction costs allocated to warrant liabilities |  | 633198 |
| &nbsp;&nbsp;Loss on issuance of warrants |  | 1633767 |
| &nbsp;&nbsp;Stock-based compensation | 80373 | 542045 |
| &nbsp;&nbsp;Change in provision for bad debts | 5423 |  |
| &nbsp;&nbsp;Change in operating assets and liabilities: |  |  |
| &nbsp;&nbsp;Accounts receivable | 33782 | (231325) |
| &nbsp;&nbsp;Inventories | 94002 | (145847) |
| &nbsp;&nbsp;Prepaid expenses, other current assets and deposits | 417738 | (3528) |
| &nbsp;&nbsp;Accounts payable and accrued liabilities | (172657) | (442797) |
| &nbsp;&nbsp;Deferred revenue | 43500 | (25150) |
| &nbsp;&nbsp;Net cash used in operating activities from continuing operations | (9141688) | (10323243) |
| &nbsp;&nbsp;Cash flows from investing activities: |  |  |
| &nbsp;&nbsp;Purchase of property and equipment | (313121) | (36654) |
| Net cash used in investing activities from continuing operations | (313121) | (36654) |
| &nbsp;&nbsp;Cash flows from financing activities: |  |  |
| &nbsp;&nbsp;Net proceeds from exercise of warrants | 2215828 | 394 |
| &nbsp;&nbsp;Net proceeds from issuance of common stock and pre-funded warrants | 5712700 | 13788923 |
| Net cash provided by financing activities from continuing operations | 7928528 | 13789317 |
| &nbsp;&nbsp;CASH FLOWS FROM DISCONTINUED OPERATIONS |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash used in operating activities | (185679) | (139089) |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash provided by investing activities | 21000 |  |
| &nbsp;&nbsp;Net cash used by discontinued operations | (164679) | (139089) |
| &nbsp;&nbsp;&nbsp;&nbsp;Net (decrease) increase in cash, cash equivalents and restricted cash | (1690960) | 3290331 |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash, cash equivalents and restricted cash at beginning of period | 7181095 | 7901800 |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash, cash equivalents and restricted cash at end of period | $5490135 | $11192131 |
| &nbsp;&nbsp;&nbsp;&nbsp;Less: cash and cash equivalents of discontinued operations | $(12458) | $(534415) |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash, cash equivalents and restricted cash of continuing operations at end of period | $5477677 | $10657716 |
| &nbsp;&nbsp;&nbsp;&nbsp;Supplemental Disclosures of Cash Flow Information: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash paid during period for interest | $— | $— |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash paid during period for income taxes | $— | $— |
| &nbsp;&nbsp;&nbsp;&nbsp;Non-cash investing and financing activities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Transaction costs included in accounts payable | $— | $390721 |
| &nbsp;&nbsp;&nbsp;&nbsp;Deemed dividend warrant modifications | $54326896 | $233087 |
| &nbsp;&nbsp;&nbsp;&nbsp;Warrants issued, cashlessly | $610 | $— |
| Property and equipment acquired and included in accounts payable | $— | $275251 |

---

See the accompanying notes to the unaudited condensed consolidated financial statements

[**Table of Contents**](#TOC)

**APPLIED DNA SCIENCES, INC. AND SUBSIDIARIES**

**FOOTNOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**JUNE 30, 2025**

**(unaudited)**

#### NOTE A — NATURE OF THE BUSINESS
Applied DNA Sciences, Inc. ("Applied DNA" or the "Company") is a biotechnology company focused on providing nucleic-acid production solutions for the biopharmaceutical and diagnostics industries. Via our LineaRx, Inc. ("LRx") subsidiary, the Company's technologies enable cell-free manufacturing of deoxyribonucleic acid ("DNA") and ribonucleic acid ("RNA"), which are essential components for a new generation of advanced biotherapeutics, such as gene therapies, adoptive cell therapies, messenger RNA ("mRNA") therapeutics and DNA vaccines, as well as diagnostic applications ("Therapeutic DNA Production Services").

Historically, the Company operated in two other business markets: (i) the manufacture and detection of DNA for industrial supply chains and security services ("DNA Tagging and Security Products and Services"), which the Company is in the process of winding down; and (ii) the detection of DNA and RNA in molecular diagnostics and genetic testing services ("MDx Testing Services"), which the Company exited on June 30, 2025. On February 13, 2025, the Company announced it was exiting its DNA Tagging and Security Products and Services business. As a result of exiting this market, during January 2025, the Company completed a workforce reduction of approximately 20% of its total headcount and approximately 13% in annual payroll costs. As a result of these actions, during the nine-month period ended June 30, 2025, the Company incurred one-time personnel-related charges of approximately $305,000.

In addition, on June 30, 2025, the Company announced a further strategic restructuring and realignment of resources to focus exclusively on its nucleic-acid production solutions for pharmaceutical and diagnostic applications. As part of actions undertaken, the Company implemented a workforce reduction of approximately 27% of its then current headcount and has ceased operations of its MDx Testing Services business that was conducted via its wholly-owned subsidiary, Applied DNA Clinical Labs ("ADCL"), effective June 27, 2025. The workforce reduction equates to a projected 23% reduction in annual payroll costs, excluding payroll expenses incurred as a result of the previously announced retirement of the Company's former Chairman and Chief Executive Officer (see Note G). Since initiating the restructuring in January 2025, the Company has reduced headcount by a total of 39% for a projected 31% total reduction in payroll expenses as compared to the fiscal year ended September 30, 2024. The projected annual payroll savings is expected to be partially offset by approximately three hundred thousand dollars ($300,000) in one-time charges related to the June 30, 2025 workforce reduction and ceasing of operations at ADCL, primarily for separation benefits. As a result of this restructuring, the operations and financial results of ADCL have been accounted for as discontinued operations (see Note J).

On March 13, 2025, the Company filed with the Secretary of State of the State of Delaware a Certificate of Amendment of its Certificate of Incorporation that effected a one-for-fifty (1:50) reverse stock split of its common stock, par value $0.001 per share, effective at 12:01 a.m. Eastern Time on March 14, 2025 (the "March 2025 Reverse Split"). In addition, on June 1, 2025, the Company filed with the Secretary of State of the State of Delaware a Certificate of Amendment of its Certificate of Incorporation that effected a one-for-fifteen (1:15) reverse stock split of its common stock, par value $0.001 per share, effective at 12:01 a.m. Eastern Time on June 2, 2025 (the "June 2025 Reverse Split") (collectively the "2025 Reverse Splits").

All warrant, option, share, and per share information in the condensed consolidated financial statements gives retroactive effect to the 2025 Reverse Splits. Please see Note E for more information.

[**Table of Contents**](#TOC)

**APPLIED DNA SCIENCES, INC. AND SUBSIDIARIES**

**FOOTNOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**JUNE 30, 2025**

**(unaudited)**

**NOTE B — BASIS OF PRESENTATION AND SUMMARY OF ACCOUNTING POLICIES**

Interim Financial Statements

The accompanying condensed consolidated financial statements as of June 30, 2025, and for the three and nine-month periods ended June 30, 2025, and 2024 are unaudited. These unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States ("GAAP") for interim financial information and are presented in accordance with the requirements of Regulation S-X of the Securities and Exchange Commission (the "SEC") and with the instructions to Form 10-Q. Accordingly, they do not include all the information and footnotes required by GAAP for complete financial statements.

In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three and nine-month periods ended June 30, 2025 are not necessarily indicative of the results that may be expected for the fiscal year ending September 30, 2025. The unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements as of and for the fiscal year ended September 30, 2024 and footnotes thereto included in the Company's Annual Report on Form 10-K filed with the SEC on December 17, 2024. The condensed consolidated balance sheet as of September 30, 2024 contained herein has been derived from the audited consolidated financial statements as of September 30, 2024 but does not include all disclosures required by GAAP.

Principles of Consolidation

The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, APDN (B.V.I.) Inc., Applied DNA Sciences India Private Limited (which currently has no operations), ADCL (see Discontinued Operations below), Spindle Biotech, Inc., Applied DNA Sciences Europe Limited (which currently has no operations) and its majority-owned subsidiary, LRx. Significant inter-company transactions and balances have been eliminated in consolidation.

Discontinued Operations

The condensed consolidated financial statements separately report discontinued operations and the results of continuing operations (see Note J). All footnotes exclude discontinued operations unless otherwise noted.

Going Concern and Management's Plan

The Company has recurring net losses. The Company incurred a net loss from continuing operations of $9,585,822 and generated negative operating cash flow from continuing operations of $9,141,688 for the nine-month period ended June 30, 2025. At June 30, 2025, the Company had cash and cash equivalents of $4,727,677. These factors raise substantial doubt about the Company's ability to continue as a going concern for one year from the date of issuance of these financial statements. The ability of the Company to continue as a going concern is dependent on the Company's ability to further implement its business plan, raise capital, and generate revenues. The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

The Company's current capital resources include cash and cash equivalents. Historically, the Company has financed its operations principally from the sale of equity and equity-linked securities.

Use of Estimates

The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Management bases its estimates on historical experience and on various assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. The most significant estimates include revenue recognition, recoverability of long-lived assets, including the values assigned to intangible assets, fair value calculations for warrants, contingencies, and management's anticipated liquidity. Management reviews its estimates on a regular basis and the effects of any material revisions are reflected in the consolidated financial statements in the period they are deemed necessary. Accordingly, actual results could differ from those estimates.

[**Table of Contents**](#TOC)

**APPLIED DNA SCIENCES, INC. AND SUBSIDIARIES**

**FOOTNOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**JUNE 30, 2025**

**(unaudited)**

#### NOTE B — BASIS OF PRESENTATION AND SUMMARY OF ACCOUNTING POLICIES, continued
Revenue Recognition

The Company follows Financial Accounting Standards Board ("FASB") Accounting Standards Codifications ("ASC"), Revenue Recognition ("ASC 606" or "Topic 606").

The Company measures revenue at the amounts that reflect the consideration to which it is expected to be entitled in exchange for transferring control of goods and services to customers. The Company recognizes revenue either at the point in time or over the period of time that performance obligations to customers are satisfied. The Company's contracts with customers may include multiple performance obligations (e.g. DNA products, maintenance, authentication services, research and development services, etc.). For such arrangements, the Company allocates revenues to each performance obligation based on their relative standalone selling price.

Due to the short-term nature of the Company's current contracts with customers, it has elected to apply the practical expedients under Topic 606 to: (1) expense as incurred, incremental costs of obtaining a contract and (2) not adjust the consideration for the effects of a significant financing component for contracts with an original expected duration of one year or less.

*Product Revenues*

The Company's DNA product revenues are accounted for/recognized in accordance with contracts with customers. The Company recognizes revenue upon satisfying its promises to transfer goods or services to customers under the terms of its contracts. These performance obligations are satisfied at the point in time the Company transfers control of the goods to the customer, which in nearly all cases is when title to and risk of loss of the goods transfer to the customer. The timing of transfer of title and risk of loss is dictated by customary or explicitly stated contract terms. The Company invoices customers upon shipment, and its collection terms range, on average, from 30 to 60 days.

*Authentication Services*

The Company recognizes revenue for authentication services upon satisfying its promises to provide services to customers under the terms of its contracts. These performance obligations are satisfied at the point in time the Company services are complete, which in nearly all cases is when the authentication report is released to the customer.

*Research and Development Services*

The Company's revenue from its research and development contracts are accounted for/recognized when the performance obligations per the contract are satisfied. These performance obligations are satisfied at the point in time, either when the Company's services are complete, or when the Company transfers control of the goods to the customer, which in nearly all cases is when title to and risk of loss of the goods transfer to the customer, or when a report is released to a customer. The timing of transfer of title and risk of loss is dictated by customary or explicitly stated contract terms. The Company invoices customers upon shipment, or completion of the services and its collection terms range, on average, from 30 to 60 days.

*Disaggregation of Revenue*

The following table presents revenues disaggregated by our business operations and timing of revenue recognition:

---

| | | |
|:---|:---|:---|
|  | **Three Month Period Ended:** | **Three Month Period Ended:** |
|  | **June 30,** <br>**2025** | **June 30,** <br>**2024** |
| Research and development services (point-in-time) | $52070 | $59900 |
| Product and authentication services (point-in-time): |  |  |
| &nbsp;&nbsp;Supply chain | 91324 | 194031 |
| &nbsp;&nbsp;Large Scale DNA Production | 160999 | 218858 |
| Total | $304393 | $472789 |

---

[**Table of Contents**](#TOC)

**APPLIED DNA SCIENCES, INC. AND SUBSIDIARIES**

**FOOTNOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**JUNE 30, 2025**

**(unaudited)**

**NOTE B — BASIS OF PRESENTATION AND SUMMARY OF ACCOUNTING POLICIES, continued**

Revenue Recognition, continued

---

| | | |
|:---|:---|:---|
|  | **Nine Month Period Ended:** | **Nine Month Period Ended:** |
|  | **June 30,** <br>**2025** | **June 30,** <br>**2024** |
| Research and development services (point-in-time) | $333059 | $202634 |
| Product and authentication services (point-in-time): |  |  |
| &nbsp;&nbsp;Supply chain | 1109786 | 936777 |
| &nbsp;&nbsp;Large Scale DNA Production | 494661 | 477010 |
| &nbsp;&nbsp;Asset marking |  | 9442 |
| Total | $1937506 | $1625863 |

---

*Contract balances*

As of June 30, 2025, the Company has entered into contracts with customers for which revenue has not yet been recognized. Consideration received from a customer prior to revenue recognition is recorded to a contract liability and is recognized as revenue when the Company satisfies the related performance obligations under the terms of the contract. The Company's contract liabilities, which are reported as deferred revenue on the condensed consolidated balance sheet, consist almost entirely of research and development contracts where consideration has been received and the development services have not yet been fully performed.

The opening and closing balances of the Company's contract balances are as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | <br>**Balance sheet classification** | **October 1,**<br>**2024** | **June 30,** <br>**2025** | **$**<br>**change** |
| Contract assets | Accounts receivables | $328252 | $199047 | $(129205) |
| Contract liabilities | Deferred revenue | $252785 | $206285 | $(46500) |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | <br>**Balance sheet classification** | **October 1,**<br>**2023** | **September 30,** <br>**2024** | **$**<br>**change** |
| Contract assets | Accounts receivables | $212966 | $328252 | $115286 |
| Contract liabilities | Deferred revenue | $270435 | $252785 | $(17650) |

---

For the three and nine-month periods ended June 30, 2025, the Company recognized $0 and $21,885, respectively, of revenue that was included in contract liabilities as of October 1, 2024.

Cash, Cash Equivalents, and Restricted Cash

For the purpose of the accompanying condensed consolidated financial statements, all highly liquid investments with a maturity of three months or less from when purchased are considered to be cash equivalents. The following table provides a reconciliation of cash, cash equivalents and restricted cash to amounts shown in the statement of cash flows.

---

| | | |
|:---|:---|:---|
|  | **June 30,** <br>**2025** | **September 30,** <br>**2024** |
| Cash and cash equivalents | $4727677 | $5852363 |
| Restricted cash | 750000 | 750000 |
| Total cash, cash equivalents and restricted cash | $5477677 | $6602363 |

---

Inventories

Inventories, which consist primarily of raw materials, work in progress and finished goods, are stated at the lower of cost or net realizable value, with cost determined by using the first-in, first-out (FIFO) method.

[**Table of Contents**](#TOC)

**APPLIED DNA SCIENCES, INC. AND SUBSIDIARIES**

**FOOTNOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**JUNE 30, 2025**

**(unaudited)**

**NOTE B — BASIS OF PRESENTATION AND SUMMARY OF ACCOUNTING POLICIES, continued**

Net Loss Per Share

The Company presents loss per share utilizing a dual presentation of basic and diluted loss per share. Basic loss per share includes no dilution and has been calculated based upon the weighted average number of common shares outstanding during the period. Dilutive common stock equivalents consist of shares issuable upon the exercise of the Company's stock options, restricted stock units and warrants.

Securities that could potentially dilute basic net loss per share in the future that were not included in the computation of diluted net loss per share because to do so would have been anti-dilutive for the three and nine-month periods ended June 30, 2025 and 2024 are as follows:

---

| | | |
|:---|:---|:---|
|  | **2025** | **2024** |
| Warrants | 3424291 | 26331 |
| Stock options | 149 | 145 |
| Total | 3424440 | 26476 |

---

Concentrations

Financial instruments and related items, which potentially subject the Company to concentrations of credit risk, consist primarily of cash, cash equivalents and trade receivables. The Company places its cash and cash equivalents with high credit quality institutions. At times, such investments may be in excess of the FDIC insurance limit. As of June 30, 2025, the Company had cash and cash equivalents of approximately $4.7 million in excess of the FDIC insurance limit.

The Company's revenues earned from sale of products and services for the three-month period ended June 30, 2025 included an aggregate of 53% and 12% from two customers within the Therapeutic DNA Production Services and the DNA Tagging and Security Products and Services segments, respectively. The Company's revenue earned from the sale of products and services for the nine-month period ended June 30, 2025 included an aggregate of 26% from one customer within the Therapeutic DNA Production Services segment, and 23%, and 12%, from two customers, respectively, within the DNA Tagging and Security Products and Services segment.

The Company's revenues earned from sale of products and services for the three and nine-month periods ended June 30, 2024 included an aggregate of 46% and 29% from one customer, respectively within the MDx Testing Services segment. The Company's revenue earned from sale of products and services for the nine - month period ended June 30, 2024, included an aggregate of 12% from one customer within the DNA Tagging and Security Products and Services segment. Three customers accounted for 82% of the Company's accounts receivable at June 30, 2025 and five customers accounted for 75% of the Company's accounts receivable at September 30, 2024.

#### Warrant Liabilities
The Company evaluates its issued warrants in accordance with ASC 480 "Distinguishing Liabilities from Equity" and ASC 815-40, "Derivatives and Hedging — Contracts in Entity's Own Equity" and concluded that due to the terms of certain of its warrant agreements, the instruments do not qualify for equity treatment. As such, certain of the Company's issued warrants were recorded as a liability on the condensed consolidated balance sheet and measured at fair value at inception and at each reporting date in accordance with ASC 820, "Fair Value Measurement", with changes in fair value recognized in the condensed consolidated statement of operations in the period of change.

[**Table of Contents**](#TOC)

**APPLIED DNA SCIENCES, INC. AND SUBSIDIARIES**

**FOOTNOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**JUNE 30, 2025**

**(unaudited)**

**NOTE B — BASIS OF PRESENTATION AND SUMMARY OF ACCOUNTING POLICIES, continued**

Segment Reporting

Historically, the Company operated in three reportable segments: (1) Therapeutic DNA Production Services; (2) MDx Testing Services; and (3) DNA Tagging and Security Products and Services. As a result of the strategic restructuring detailed above, regarding the closure of its clinical laboratory, effective June 27, 2025, the Company's MDx Testing Services segment is being reported in discontinued operations. Resources are allocated by the Company's Chief Executive Officer ("CEO"), Chief Financial Officer ("CFO") and Chief Legal Officer and President of LineaRx, Inc. ("CLO") whom, collectively, the Company has determined to be our Chief Operating Decision Maker ("CODM"). The following is a brief description of our reportable segments.

**Therapeutic DNA Production Services** — Segment operations consist of the Company's nucleic-acid production solutions for the biopharmaceutical and diagnostics industries including LineaDNA, LineaRNAP and LineaIVT.

**DNA Tagging and Security Products and Services** — Segment operations consist of the manufacture and detection of DNA for industrial supply chains and security services. As discussed above, on February 13, 2025, the Company announced it was exiting its DNA Tagging and Security Products and Services business segment. The Company continues to strategically exit contracts relating to this segment and currently plans to continue to service certain of its existing DNA Tagging and Security Products and Services customer contracts.

The Company evaluates the performance of its segments and allocates resources to them based on revenues and operating income (losses). Operating income (loss) includes intersegment revenues, as well as a charge allocating all corporate headquarters costs. Since each vertical has shared employee resources, payroll and certain other general expenses such as rent, and utilities were allocated based on an estimate by management of the percentage of employee time spent in each vertical. Segment assets are not reported to, or used by, the CODM to allocate resources to, or assess performance of, the segments and therefore, total segment assets have not been disclosed.

Fair Value of Financial Instruments

The valuation techniques utilized are based upon observable and unobservable inputs. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect internal market assumptions. These two types of inputs create the following fair value hierarchy:

Level 1 — Unadjusted quoted prices in active markets for identical assets or liabilities.

Level 2 — Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related asset or liabilities.

Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of assets or liabilities.

The Company utilizes observable market inputs (quoted market prices) when measuring fair value whenever possible.

The development and determination of the unobservable inputs, as well as the valuation policies and procedures for Level 3 fair value measurements and fair value calculations are the responsibility of the Company's accounting and finance department and are approved by the Chief Financial Officer.

As of June 30, 2025, there were no transfers between Levels 1, 2 and 3 of the fair value hierarchy.

[**Table of Contents**](#TOC)

**APPLIED DNA SCIENCES, INC. AND SUBSIDIARIES**

**FOOTNOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**JUNE 30, 2025**

**(unaudited)**

**NOTE B — BASIS OF PRESENTATION AND SUMMARY OF ACCOUNTING POLICIES, continued** 

Recent Accounting Standards

In November 2024, the FASB issued Accounting Standards Update (ASU) No. 2024-03, *Disaggregation of Income Statement Expenses*, that requires public companies to provide additional disclosure of the nature of expenses included in the income statement. This ASU requires disclosure about specific types of expenses included in the expense captions presented on the face of the income statement as well as disclosures about selling expenses. This guidance is effective within annual reporting periods beginning after December 15, 2027. The requirements will be applied prospectively with the option for retrospective application, early adoption is permitted. The Company is currently evaluating the impact of this ASU on its condensed consolidated statement of operations and on its disclosures.

In December 2023, the FASB issued Accounting Standards Update (ASU) No. 2023-09, *Income Taxes (Topic 740): Improvements to Income Tax Disclosures*, that enhances the transparency of income tax disclosures by expanding annual disclosure requirements related to the rate reconciliation and income taxes paid. The guidance is effective for fiscal years beginning after December 15, 2024, with early adoption permitted, and should be applied prospectively with the option of retrospective application. The Company is currently evaluating the impact of adopting this ASU on its disclosures.

In November 2023, the FASB issued ASU No. 2023-07, "Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosure." The ASU updates reportable segment disclosure requirements, primarily through requiring enhanced disclosures about significant segment expenses and information used to assess segment performance. These disclosures are required quarterly. The ASU is effective for fiscal years beginning after December 15, 2023 and interim periods beginning after December 15, 2024, with early adoption permitted. The Company adopted this ASU as of October 1, 2024 and updated its segment reporting disclosures accordingly for the three and nine-month periods ended June 30, 2025 and 2024.

In August 2020, the FASB issued ASU No. 2020-06, "Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging— Contracts in Entity's Own Equity (Subtopic 815-40)." The objective of this update is to simplify the accounting for convertible preferred stock by removing the existing guidance in ASC 470-20, "Debt: Debt with Conversion and Other Options," that requires entities to account for beneficial conversion features and cash conversion features in equity, separately from the host convertible debt or preferred stock. The guidance in ASC 470-20 applies to convertible instruments for which the embedded conversion features are not required to be bifurcated from the host contract and accounted for as derivatives. In addition, the amendments revise the scope exception from derivative accounting in ASC 815-40 for freestanding financial instruments and embedded features that are both indexed to the issuer's own stock and classified in stockholders' equity, by removing certain criteria required for equity classification. These amendments are expected to result in more freestanding financial instruments qualifying for equity classification (and, therefore, not accounted for as derivatives), as well as fewer embedded features requiring separate accounting from the host contract. This amendment also further revises the guidance in ASU 260, "Earnings per Share," to require entities to calculate diluted earnings per share (EPS) for convertible instruments by using the if-converted method. In addition, entities must presume share settlement for purposes of calculating diluted EPS when an instrument may be settled in cash or shares. The amendments in ASU 2020-06 were effective for the Company beginning October 1, 2024. The adoption of ASU 2020-06 did not have a significant impact on the Company's condensed consolidated financial statements.

#### NOTE C — INVENTORIES
Inventories consist of the following:

---

| | | |
|:---|:---|:---|
|  | **June 30,** <br>**2025** | **September 30,** <br>**2024** |
|  | **(unaudited)** |  |
| Raw materials | $101537 | $75141 |
| Work-in-progress | 233650 | 221250 |
| Finished goods | 3536 | 136334 |
| Total | $338723 | $432725 |

---

[**Table of Contents**](#TOC)

**APPLIED DNA SCIENCES, INC. AND SUBSIDIARIES**

**FOOTNOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**JUNE 30, 2025**

**(unaudited)**

#### NOTE D — ACCOUNTS PAYABLE AND ACCRUED LIABILITIES
Accounts payable and accrued liabilities are as follows:

---

| | | |
|:---|:---|:---|
|  | **June 30,** <br>**2025** | **September 30,** <br>**2024** |
|  | **(unaudited)** |  |
| Accounts payable | $614759 | $1138187 |
| Accrued salaries payable | 902328 | 480760 |
| Other accrued expenses | 47620 | 118419 |
| Total | $1564707 | $1737366 |

---

Included in accrued salaries and payable is $287,500 for severance payments to be made for former employees from the June 30, 2025 workforce reduction disclosed in Note A above. This $287,500 was recorded to the following accounts within the condensed consolidated statement of operations for the three and nine-month periods ended June 30, 2025; $97,111 in net loss from discontinued operations, $112,481 to selling, general and administrative expenses, and $77,908 to cost of product revenues.

**NOTE E — CAPITAL STOCK**

Reverse Stock Splits

March 2025 Reverse Split

On September 30, 2024, the Company held its annual shareholders' meeting where its stockholders approved a proposal to grant the Company's Board of Directors discretionary authority for twelve months to amend the Company's Certificate of Incorporation to authorize a reverse stock split in the range from one-for five to one-for fifty. The Company's Board of Directors determined on March 3, 2025, that the split ratio would be one-for-fifty shares.

The March 2025 Reverse Split was effected as of 12:01 a.m. Eastern Time on March 14, 2025 and combined each fifty shares of the Company's outstanding common stock into one share of common stock, without any change in the par value per share.

June 2025 Reverse Split

On May 22, 2025, the Company held its annual shareholders' meeting where its stockholders approved a proposal to grant the Company's Board of Directors discretionary authority for twelve months to amend the Company's Certificate of Incorporation to authorize a reverse stock split in the range from one-for five to one-for fifty. The Company's Board of Directors determined on May 27, 2025 that the split ratio would be one-for-fifteen shares.

The June 2025 Reverse Split was effected as of 12:01 a.m. Eastern Time on June 2, 2025 and combined each fifteen shares of the Company's outstanding common stock into one share of common stock, without any change in the par value per share.

Moreover, each of the 2025 Reverse Splits correspondingly adjusted: (i) the per share exercise price and the number of shares issuable upon the exercise of all outstanding options; and (ii) the number of shares underlying any of our outstanding warrants by adjusting the conversion ratio for each instrument and increasing the applicable exercise price or conversion price in accordance with the terms of each instrument and based on the reverse stock split ratio. No fractional shares were issued in connection with the 2025 Reverse Splits. Any fractional shares resulting from the 2025 Reverse Splits were rounded up to the nearest whole share. In addition, each of the 2025 Reverse Splits triggered an exercise price reset mechanism ("Price Reset Mechanism") contained in certain warrants which resulted in the number of shares and exercise price of such warrants being further adjusted, as described in more detail below.

[**Table of Contents**](#TOC)

**APPLIED DNA SCIENCES, INC. AND SUBSIDIARIES**

**FOOTNOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**JUNE 30, 2025**

**(unaudited)**

**NOTE E — CAPITAL STOCK, continued**

Registered Direct Offering and Concurrent Private Placement

On October 31, 2024, the Company closed a registered direct offering (the "October Registered Direct Offering") in which, pursuant to the Securities Purchase Agreement dated October 30, 2024 (the "October Purchase Agreement"), by and between the Company and certain institutional investors (the "October Purchasers"), the Company issued and sold 25,663 shares of the Company's common stock and pre-funded warrants (the "October Pre-Funded Warrants") to purchase up to 1,420 shares of the Company's common stock, and (ii) in a concurrent private placement (the "October Private Placement", and together with the October Registered Direct Offering the "October Offering"), unregistered Series C Common Stock Purchase Warrants (the "October Series C Warrants") to purchase up to 27,083 shares of common stock and unregistered Series D Common Stock Purchase Warrants (the "October Series D Warrants", and together with the October Series C Warrants, the "October Series Warrants", and, together with the October Pre-Funded Warrants and the October Series C Warrants, the "October Warrants") to purchase up to 27,083 shares of common stock. The purchase price for each share of common stock and accompanying October Series C Warrant and October Series D Warrant was $240.00 and the purchase price for each October Pre-Funded Warrant and accompanying October Series C Warrant and October Series D Warrant was $240.00. Craig-Hallum Capital Group LLC ("Craig-Hallum") acted as placement agent in connection with the October Offering. Pursuant to that certain engagement letter, dated August 23, 2024, by and between the Company and Craig-Hallum, the Company agreed to pay Craig-Hallum a cash placement fee equal to 6.0% of the aggregate gross proceeds raised in the October Offering from sales arranged for by Craig-Hallum. Subject to certain conditions, the Company also agreed to reimburse certain expenses of Craig-Hallum in connection with the October Offering, including but not limited to legal fees, up to a maximum of $100,000. The Company also agreed to issue to Craig-Hallum, or its respective designees, warrants (the "Placement Agent Warrants") to purchase up to 1,354 shares of the Company's common stock (which equals 5.0% of the number of shares of the Company's common stock and October Pre-Funded Warrants offered).

The Company received net proceeds from the October Offering, after deducting placement agent fees and other offering expenses payable by the Company, of approximately $5.7 million.

The exercisability of the October Series Warrants and the Placement Agent Warrants required approval of the Company's stockholders, which was obtained at the Company's annual meeting held on May 22, 2025. Each October Series C Warrant has an exercise price of $240.00 per share of the Company's common stock, became exercisable on May 23, 2025 (the "Initial Exercise Date") and will expire on the five-year anniversary of the Initial Exercise Date. Each October Series D Warrant has an exercise price of $240.00 per share of the Company's common stock, became exercisable on the Initial Exercise Date, and will expire on the 18-month anniversary of the Initial Exercise Date. The October Pre-Funded Warrants have an exercise price of $0.0001 per share, were immediately exercisable and can be exercised at any time after their original issuance until such October Pre-Funded Warrants are exercised in full. All of the October Pre-Funded Warrants were exercised during the nine-month period ended June 30, 2025. Each Placement Agent Warrant has an exercise price of $240.00, became exercisable on the Initial Exercise Date and will expire on October 30, 2029.

Under the alternate cashless exercise option of the October Series D Warrants, the holder of an October Series D Warrant has the right to receive an aggregate number of shares equal to the product of (x) the aggregate number of shares of the Company's common stock that would be issuable upon a cash exercise of the October Series D Warrant and (y) 1.0. In addition, the October Series D Warrants include a provision that resets their exercise price in the event of a reverse split of the Company's common stock, to a price equal to the lesser of (i) the then exercise price and (ii) lowest volume weighted average price (VWAP) during the period commencing five trading days immediately preceding and the five trading days commencing on the date the Company effects a reverse stock split in the future with a proportionate adjustment to the number of shares underlying the October Series D Warrants, subject to a floor of $47.55.

On March 14, 2025, the Company completed the March 2025 Reverse Stock Split. As a result, the exercise price reset mechanism was triggered, which resulted in the number of shares of common stock issuable upon exercise of the October Series D Warrants increasing from 27,083 to 136,698. The exercise price of the October Series D Warrants was adjusted from $240.00 per share to $47.55 per share.

[**Table of Contents**](#TOC)

**APPLIED DNA SCIENCES, INC. AND SUBSIDIARIES**

**FOOTNOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**JUNE 30, 2025**

**(unaudited)**

**NOTE E — CAPITAL STOCK, continued**

*Registered Direct Offering and Concurrent Private Placement, continued*

The October Series Warrants and the Placement Agent Warrants are not registered under the Securities Act of 1933, as amended (the "Securities Act"). The October Series Warrants and the Placement Agent Warrants were issued, and the shares of the Company's common stock issuable upon exercise thereof will be issued (unless an effective registration statement is available), in reliance on the exemptions from registration provided by Section 4(a)(2) under the Securities Act and Regulation D promulgated thereunder, for transactions not involving a public offering.

Pursuant to the October Purchase Agreement, within 20 calendar days from the date of the October Purchase Agreement, the Company agreed to file a registration statement on Form S-1 providing for the resale by the purchasers of the shares of common stock issuable upon exercise of the October Series Warrants and the Placement Agent Warrants. The registration statement registering such shares was declared effective by the SEC on January 17, 2025.

In the event of any fundamental transaction, as described in the October Warrants and generally including any merger with or into another entity, sale of all or substantially all of the Company's assets, tender offer or exchange offer, reclassification of the shares of common stock, or the acquisition of greater than 50% of the Company's then outstanding shares of common stock by a person or persons, subject to certain exceptions, then upon any subsequent exercise of an October Warrant, the holder will have the right to receive as alternative consideration, for each share of the Company's common stock that would have been issuable upon such exercise immediately prior to the occurrence of such fundamental transaction, the number of shares of common stock of the successor or acquiring corporation of the Company, if it is the surviving corporation, and any additional consideration receivable upon or as a result of such transaction by a holder of the number of shares of common stock for which the October Warrant is exercisable immediately prior to such event. Notwithstanding the foregoing, in the event of a fundamental transaction, the holders of the October Warrants have the right to require the Company or a successor entity to purchase the October Warrants for cash in the amount of the Black Scholes Value (as defined in the October Warrants) of the unexercised portion of the October Warrants concurrently with or within 30 days following the consummation of a fundamental transaction. However, in the event of a fundamental transaction which is not in the Company's control or in which the consideration payable consists of equity securities of a successor entity that is quoted or listed on a nationally recognized securities exchange, the holders of the October Warrants will only be entitled to receive from the Company or its successor entity, as of the date of consummation of such fundamental transaction the same type or form of consideration (and in the same proportion), at the Black Scholes Value of the unexercised portion of the October Warrants that is being offered and paid to the holders of common stock in connection with the fundamental transaction, whether that consideration is in the form of cash, stock or any combination of cash and stock, or whether the holders of common stock are given the choice to receive alternative forms of consideration in connection with the fundamental transaction.

*Amendment to May 2024 Series A Warrants*

On October 30, 2024, the Company entered into amendments (the "Warrant Amendments") with certain holders of an aggregate of 12,205 Series A Warrants issued in a transaction which closed in May 2024 (the "May 2024 Series A Warrants"). The Warrant Amendments amended the May 2024 Series A Warrants to revise the Price Reset Mechanism of the May 2024 Series A Warrants, which, subject to certain exceptions, provided for an adjustment to the exercise price and number of shares underlying the May 2024 Series A Warrants upon the Company's issuance of common stock or common stock equivalents at a price per share that is less than the exercise price of the May 2024 Series A Warrants. The Warrant Amendments amended the Price Reset Mechanism such that the Floor Price (as defined in the May 2024 Series A Warrants) will not be lower than $150.00. In addition, the Warrant Amendments revised the definition of "Material Subsidiary" in Section 3(d) of the May 2024 Series A Warrants to clarify that Applied DNA Clinical Labs LLC is not a Material Subsidiary.

[**Table of Contents**](#TOC)

**APPLIED DNA SCIENCES, INC. AND SUBSIDIARIES**

**FOOTNOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**JUNE 30, 2025**

**(unaudited)**

**NOTE E — CAPITAL STOCK, continued**

*Amendment to May 2024 Series A Warrants, continued*

In connection with the October Registered Direct Offering, the Price Reset Mechanism in the May 2024 Series A Warrants was triggered, which resulted in the number of shares of common stock issuable upon exercise of the May 2024 Series A Warrants increasing from 12,308 to 122,521. The exercise price of the May 2024 Series A Warrants was adjusted from $1,492.50 per share to $150.00 per share with the respect to the May 2024 Series A Warrants amended by the Warrant Amendment and to $141.75 with respect to the May 2024 Series A Warrants not amended by the Warrant Amendment. As a result of the March 2025 Reverse Stock Split, the exercise Price Reset Mechanism was triggered for the May 2024 Series A Warrants, which resulted in the number of shares of common stock issuable upon exercise of the May 2024 Series A Warrants increasing from 122,521 to 655,676. The exercise price of the May 2024 Series A Warrants was adjusted from $150.00 per share for the amended May 2024 Series A Warrants and $141.75 per share for the May 2024 Series A Warrants that were not amended to $26.91 per share for all of the May 2024 Series A warrants.

As a result of the June 2025 Reverse Stock Split, the exercise Price Reset Mechanism was triggered for the May 2024 Series A Warrants, which resulted in the number of shares of common stock issuable upon exercise of the May 2024 Series A Warrants increasing from 626,555 to 3,286,016. The exercise price of the May 2024 Series A Warrants was adjusted from $26.91 per share to $5.13 per share.

*May 2024 Series B Warrants Price and Share Adjustment*

As a result of the March 2025 Reverse Stock Split, the exercise Price Reset Mechanism was triggered for the May 2024 Series B Warrants, which resulted in the number of shares of common stock issuable upon exercise of the May 2024 Series B Warrants increasing from 3,009 to 163,019. The exercise price of the May 2024 Series B Warrants was adjusted from $1,492.50 per share to $26.91 per share.

As a result of the June 2025 Reverse Stock Split, the exercise Price Reset Mechanism was triggered for the May 2024 Series B Warrants, which resulted in the number of shares of common stock issuable upon exercise of the May 2024 Series B Warrants, increasing from 54,558 to 286,123. The exercise price of the May 2024 Series B Warrants was adjusted from $26.91 per share to $5.13 per share.

The incremental change in fair value as a result of the modifications for the May 2024 Series A Warrants, the May 2024 Series B Warrants and the October 2024 Series D Warrants for the three and nine-month periods ended June 30, 2025 was $15,500,244 and $54,326,896, respectively, and is recorded as a deemed dividend in the condensed consolidated statement of operations.

*Nasdaq Minimum Bid Price Requirement Deficiency Notifications*

On November 12, 2024, the Company received written notice (the "Notification Letter") from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it was not in compliance with the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share, and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of thirty (30) consecutive business days (collectively, the "Bid Price Rule"). Based on the closing bid price of the Company's common stock for the thirty-one (31) consecutive business days from September 27, 2024 to November 11, 2024, the Company no longer met the requirements of the Bid Price Rule. The Notification Letter did not impact the Company's listing on The Nasdaq Capital Market at that time. The Notification Letter stated that the Company had 180 calendar days, or until May 12, 2025, to regain compliance with the Bid Price Rule.

On April 7, 2025, the Company received written notice (the "Compliance Notice") from Nasdaq informing the Company that it has regained compliance with Nasdaq Listing Rule 5550(a)(2), which requires that companies listed on The Nasdaq Capital Market maintain a minimum bid price of $1.00 per share. Nasdaq notified the Company in the Compliance Notice that, from March 14, 2025 to April 4, 2025, the closing bid price of the Company's common stock had been at $1.00 per share or greater and, accordingly, the Company had regained compliance with Nasdaq Listing Rule 5550(a)(2) and that the matter was now closed.

[**Table of Contents**](#TOC)

**APPLIED DNA SCIENCES, INC. AND SUBSIDIARIES**

**FOOTNOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**JUNE 30, 2025**

**(unaudited)**

**NOTE E — CAPITAL STOCK, continued**

*Nasdaq Minimum Bid Price Requirement Deficiency Notifications, continued*

The Company received written notice dated May 30, 2025 (the "May 2025 Notification Letter") from Nasdaq that the Company no longer satisfied the Bid Price Rule. Based on the closing bid price of the Company's common stock, for the thirty-two (32) consecutive business days from April 14, 2025 to May 29, 2025, the Company did not comply with the Bid Price Rule.

The May 2025 Notification Letter further indicated that, pursuant to Nasdaq Listing Rule 5810(c)(3)(A)(iv), the Company was not eligible for a compliance period under Nasdaq Listing Rule 5810(c)(3)(A) due to the fact that the Company had effected a reverse stock split over the prior one-year period or had effected one or more reverse stock splits over the prior two-year period with a cumulative ratio of 250 shares or more to one; accordingly, the Company was informed that its securities were subject to delisting from Nasdaq unless the Company timely requested a hearing before the Nasdaq Hearings Panel (the "Panel"). The Company timely requested a hearing, which request will stay any further suspension or delisting action by Nasdaq at least pending the ultimate conclusion of the hearing process.

On July 2, 2025, the Company received written notice (the "July 2025 Compliance Notice") from Nasdaq informing the Company that it had regained compliance with the Bid Price Rule, and that the Company is therefore in compliance with the Nasdaq Capital Market's listing requirements. Nasdaq also notified the Company in the July 2025 Compliance Notice that the hearing before the Panel previously scheduled to take place on July 15, 2025 was cancelled and the Company's securities will continue to be listed and traded on Nasdaq.

#### NOTE F —WARRANTS AND STOCK OPTIONS
Warrants

The following table summarizes the changes in warrants outstanding. These warrants were granted as part of financing transactions, as well as in lieu of cash compensation for services performed or as financing expenses in connection with the sales of the Company's common stock. See Note E for details on the warrant activity during the nine-month period ended June 30, 2025.

---

| | | |
|:---|:---|:---|
|  | <br>**Number of**<br>**Shares** | **Weighted**<br>**Average**<br>**Exercise**<br>**Price Per**<br>**Share** |
| Balance at October 1, 2024 | 26332 | $2085.00 |
| Granted | 4706994 | 8.42 |
| Exercised | (467859) | 16.41 |
| Cancelled or expired | (841176) | 9.24 |
| Balance at June 30, 2025 | 3424291 | $12.36 |

---

During the three and nine-month periods ended June 30, 2025, 43,512 and 157,759, respectively, of the May 2024 Series B Warrants were exercised cashlessly and resulted in the issuance of 130,537 and 473,277 shares of the Company's common stock, respectively. Subsequent to June 30, 2025 an additional 111,000 May 2024 Series B Warrants were exercised cashlessly and resulted in the issuance of 333,000 shares of the Company's common stock.

During the three and nine - month periods ended June 30, 2025, 136,698 of the October 2024 Series D Warrants were exercised cashlessly and resulted in the issuance of 136,698 shares of the Company's common stock. As of June 30, 2025, there were no October 2024 Series D Warrants outstanding.

During the three and nine-month periods ended June 30, 2025, an aggregate of 138,557 and 171,981 May 2024 Series A Warrants were exercised, respectively, for aggregate total proceeds of $723,055 and $2,220,459 for the three and nine-month periods ended June 30, 2025, respectively. Subsequent to June 30, 2025 an additional 56,965 May 2024 Series A Warrants were exercised for aggregate total proceeds of approximately $292,305.

[**Table of Contents**](#TOC)

**APPLIED DNA SCIENCES, INC. AND SUBSIDIARIES**

**FOOTNOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**JUNE 30, 2025**

**(unaudited)**

**NOTE F —WARRANTS AND STOCK OPTIONS, continued**

Stock Options

On May 22, 2025, at the Company's annual shareholders' meeting, an amendment to the Company's 2020 Equity Incentive Plan to increase the number of authorized shares of common stock reserved for issuance by 200,000 shares was approved. As of June 30, 2025 there are 200,355 shares available under the Company's 2020 Equity Incentive Plan.

#### NOTE G — COMMITMENTS AND CONTINGENCIES
Operating Leases

The Company leases office space under an operating lease in Stony Brook, New York for its corporate headquarters. The lease is for a 30,000 square foot building. The Company entered into an amended lease agreement on February 1, 2023. The initial term is for three years and expires on February 1, 2026. The lease for the corporate headquarters requires monthly payments of $48,861, which is adjusted annually based on the US Consumer Price Index ("CPI") and was adjusted to monthly payments of $52,440 commencing on February 1, 2025. In lieu of a security deposit, the Company provided a standby letter of credit of $750,000. In addition, the Company also had 2,500 square feet of laboratory space, for which it entered into an amended lease agreement on February 1, 2023. The initial lease term for the laboratory space was one year from the commencement date and was extended until January 31, 2025. Effective February 1, 2025, the Company extended this lease for 2,000 square feet of laboratory space until January 31, 2026. On February 28, 2025, the Company vacated one of its laboratory suites and currently leases 1,000 square feet under this lease amendment. The base rent for the new lease term is monthly payments of $4,346 and the lease is terminable by the Company upon one month's written notice to the landlord. The Company terminated the lease for the remaining 1,000 square fee, effective July 31, 2025. The total rent expense for the three and nine-month periods ended June 30, 2025 was $157,320 and $498,416, respectively.

Employment Agreement

On June 16, 2025, Dr. James A. Hayward informed the Company of his intention to retire from the Company and that he would step down from his positions as Chief Executive Officer, member of the Company's board of directors (the "Board") and Chairman of the Board effective June 18, 2025. Dr. Hayward's resignation was not the result of any dispute or disagreement with the Company or the Board on any matter relating to the Company's operations, policies or practices.

In connection with Dr. Hayward's retirement, Dr. Hayward and the Company entered into a separation agreement dated June 16, 2025 (the "Separation Agreement"), pursuant to which the Company shall pay to Dr. Hayward, contingent upon his compliance with the terms of the Separation Agreement, the total gross amount of $450,000 to be paid over a period of eight months from the date of first payment, with the first installment being paid on or before July 15, 2025. The Separation Agreement also provides for a customary general release of claims in favor of the Company and customary post-employment covenants, including with respect to confidentiality and non-disparagement.

On June 17, 2025, the Board elected Judith Murrah, the Company's current President, as Chief Executive Officer and as Chairperson and a member of the Board effective June 18, 2025. Effective June 30, 2025, Ms. Murrah voluntarily agreed to a fifteen percent (15%) temporary reduction in her annual base salary in connection with the Company's efforts to reduce its ongoing operating expenses. Ms. Murrah's reduced annual base salary is $340,000. The reduction is expected to end on a future date to be agreed by and between Ms. Murrah and the Compensation Committee of the Board.

Litigation

From time to time, the Company may become involved in various lawsuits and legal proceedings which arise in the ordinary course of business. When the Company is aware of a claim or potential claim, it assesses the likelihood of any loss or exposure. If it is probable that a loss will result and the amount of the loss can be reasonably estimated, the Company will record a liability for the loss. In addition to the estimated loss, the recorded liability includes probable and estimable legal costs associated with the claim or potential claim. Litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm the Company's business. There is no pending litigation involving the Company at this time.

[**Table of Contents**](#TOC)

**APPLIED DNA SCIENCES, INC. AND SUBSIDIARIES**

**FOOTNOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**JUNE 30, 2025**

**(unaudited)**

**NOTE H – SEGMENT INFORMATION**

As detailed in Note B above, the Company currently has two reportable segments: (1) Therapeutic DNA Production Services; and (2) DNA Tagging and Security Products and Services. For the three and six-month periods ended June 30 2024, the MDx Testing Services segment is also presented. Resources are allocated by our CEO, COO, CFO and CLO whom, collectively, the Company has determined to be our CODM.

Information regarding operations by segment for the three-month period ended June 30, 2025 is as follows:

---

| | | | |
|:---|:---|:---|:---|
|  | **Therapeutic DNA**<br>**Production** | **DNA Tagging and**<br>**Security Products** | <br>**Consolidated** |
| Revenues: |  |  |  |
| &nbsp;&nbsp;Product revenues | $160999 | $34263 | $195262 |
| &nbsp;&nbsp;Service revenues | 52070 | 57061 | 109131 |
| Less intersegment revenues |  |  |  |
| Total revenues | $213069 | $91324 | $304393 |
| Gross profit | $41528 | $(36398) | $5130 |
| Segment operating expenses |  |  |  |
| Selling, general and administrative | $1074583 | $119770 | $1194353 |
| Research and development | 705053 | (42909) | 662144 |
| Total segment operating expenses | $1779636 | $76861 | $1856497 |
| Loss from segment operations (a) | $(1738108) | $(113259) | $(1851367) |

---

Information regarding operations by segment for the three-month period ended June 30, 2024 is as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Therapeutic DNA**<br>**Production** | **MDx Testing**<br>**Services and Kits** | **DNA Tagging and**<br>**Security Products** | <br>**Consolidated** |
| Revenues: |  |  |  |  |
| &nbsp;&nbsp;Product revenues | $218858 | $— | $27786 | $246644 |
| &nbsp;&nbsp;Service revenues | 59901 |  | 166244 | 226145 |
| &nbsp;&nbsp;Clinical laboratory service revenues |  | 325930 |  | 325930 |
| Less intersegment revenues |  | (1200) |  | (1200) |
| Total revenues  | 278759 | 324730 | 194030 | 797519 |
| Gross profit | 194341 | (12260) | 63151 | 245232 |
| Segment operating expenses |  |  |  |  |
| Selling, general and administrative | $852919 | $165983 | $604955 | $1623857 |
| Research and development | 660515 | 52917 | 152149 | 865581 |
| Total segment operating expenses | $1513434 | $218900 | $757104 | $2489438 |
| Loss from segment operations (a) | $(1319093) | $(231160) | $(693953) | $(2244206) |

---

[**Table of Contents**](#TOC)

**APPLIED DNA SCIENCES, INC. AND SUBSIDIARIES**

**FOOTNOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**JUNE 30, 2025**

**(unaudited)**

**NOTE H – SEGMENT INFORMATION, continued**

Information regarding operations by segment for the nine-month period ended June 30, 2025 is as follows:

---

| | | | |
|:---|:---|:---|:---|
|  | **Therapeutic DNA**<br> **Production** | **DNA Tagging and**<br> **Security Products** | <br> **Consolidated** |
| Revenues: |  |  |  |
| &nbsp;&nbsp;Product revenues | $668407 | $571340 | $1239747 |
| &nbsp;&nbsp;Service revenues | 159312 | 538447 | 697759 |
| &nbsp;&nbsp;Clinical laboratory service revenues |  |  |  |
| Less intersegment revenues |  |  |  |
| Total revenues  | $827719 | $1109787 | $1937506 |
| Gross profit | $428187 | $578700 | $1006887 |
| Segment operating expenses |  |  |  |
| Selling, general and administrative | $2931352 | $1155551 | $4086903 |
| Research and development | 2146426 | 138293 | 2284719 |
| Total segment operating expenses | $5077778 | $1293844 | $6371622 |
| (Loss) income from segment operations (a) | $(4649591) | $(715144) | $(5364735) |

---

Information regarding operations by segment for the nine-month period ended June 30, 2024 is as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Therapeutic DNA**<br> **Production** | **MDx Testing**<br> **Services and Kits** | **DNA Tagging and**<br> **Security Products** | <br> **Consolidated** |
| Revenues: |  |  |  |  |
| &nbsp;&nbsp;Product revenues | $477010 | $&nbsp;&nbsp;&nbsp;&nbsp;— | $470076 | $947086 |
| &nbsp;&nbsp;Service revenues | 202635 |  | 476142 | 678777 |
| &nbsp;&nbsp;Clinical laboratory service revenues |  | 1004250 |  | 1004250 |
| Less intersegment revenues |  | (11800) |  | (11800) |
| Total revenues  | $679645 | $992450 | $946218 | $2618313 |
| Gross profit | $462464 | $(56703) | $366219 | $771980 |
| Segment operating expenses |  |  |  |  |
| Selling, general and administrative | $2371501 | $771499 | $1758312 | $4901312 |
| Research and development | 1834551 | 198061 | 586215 | 2618827 |
| Total segment operating expenses | $4206052 | $969560 | $2344527 | $7520139 |
| (Loss) income from segment operations (a) | $(3743588) | $(1026263) | $(1978308) | $(6748159) |

---

[**Table of Contents**](#TOC)

**APPLIED DNA SCIENCES, INC. AND SUBSIDIARIES**

**FOOTNOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**JUNE 30, 2025**

**(unaudited)**

**NOTE H – SEGMENT INFORMATION, continued**

Reconciliation of loss from segment operations to Corporate (loss) income for the three-month periods ended June 30, 2025 and 2024 is as follows:

---

| | | |
|:---|:---|:---|
|  | **June 30,**  | **June 30,**  |
|  | **2025** | **2024** |
| Loss from operations of reportable segments | $(1851367) | $(2244206) |
| General corporate expenses (b) | (1842693) | (1102485) |
| Interest income | 40267 | 36295 |
| Unrealized gain on change in fair value of warrants classified as a liability | 6410 | 5160000 |
| Net loss from discontinued operations | (336195) |  |
| Other (expense) income, net | (531) | (103) |
| Consolidated net (loss) income  | $(3984109) | $1849501 |

---

Reconciliation of loss from segment operations to Corporate loss for the nine-month periods ended June 30, 2025 and 2024 is as follows:

---

| | | |
|:---|:---|:---|
|  | **June 30,**  | **June 30,**  |
|  | **2025** | **2024** |
| Loss from operations of reportable segments | $(5364735) | $(6748159) |
| General corporate expenses (b) | (4684821) | (4005351) |
| Interest income | 168672 | 84972 |
| Unrealized gain on change in fair value of warrants classified as a liability | 318840 | 9564000 |
| Unrealized loss on change in fair value of warrants classified as a liability - warrant modification |  | (394000) |
| Transaction costs allocated to warrant liabilities |  | (633198) |
| Loss on issuance of warrants |  | (1633767) |
| Other (expense) income, net | (23778) | (9060) |
| Net loss from discontinued operations | (403120) |  |
| Consolidated net loss | $(9988942) | $(3774563) |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Segment operating loss consists of net sales, less cost of sales, specifically identifiable research and development, and selling, general and administrative expenses.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) General corporate expenses consist of selling, general and administrative expenses that are not specifically identifiable to a segment.

**NOTE I – FAIR VALUE OF FINANCIAL INSTRUMENTS**

The Company's financial instruments at fair value are measured on a recurring basis. Related unrealized gains or losses are recognized in unrealized gain (loss) on change in fair value of the warrants classified as a liability in the condensed consolidated statements of operations. For additional disclosures regarding methods and assumptions used in estimating fair values of these financial instruments, see Note B.

The following tables present the fair value of the Company's financial instruments as of June 30, 2025

---

| | |
|:---|:---|
|  | **Fair value at**<br>**June 30, 2025** |
| **Liabilities:** |  |
| Common Warrants | $100 |
| Series A Warrants | $10 |
| Series A Warrants - modified | $50 |
| Private Common Warrants | $1000 |

---

[**Table of Contents**](#TOC)

**APPLIED DNA SCIENCES, INC. AND SUBSIDIARIES**

**FOOTNOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**JUNE 30, 2025**

**(unaudited)**

**NOTE I – FAIR VALUE OF FINANCIAL INSTRUMENTS, continued**

The fair value of the warrants classified as a liability as of June 30, 2025, was determined using the Black Scholes and Probability Weighted Expected Return models. The fair value for the warrants classified as a liability as of June 30, 2025, was calculated using the following assumptions:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | <br>**Common** <br>**Warrants** | <br>**Series A** <br>**Warrants** | **Series A** <br>**Warrants –** <br>**modified** | **Private** <br>**Common** <br>**Warrants** |
| Stock price | $5.15 | $5.15 | $5.15 | $5.15 |
| Exercise price | $9135 | $60000 | $9135 | $9135 |
| Dividend yield | 0% | 0% | 0% | 0% |
| Selected Volatility | 187.50% | 187.50% | 187.50% | 172.50% |
| Risk free rate | 3.69% | 3.72% | 3.69% | 3.72% |
| Fundamental transaction probability | 30.00% | 30.00% | 30.00% | 30.00% |
| Fundamental transaction Black Scholes Volatility | 214.00% | 100.00% | 214.0% | 183.30% |
| Fundamental transaction timing | 12/31/2025 | 12/31/2025 | 12/31/2025 | 12/31/2025 |

---

The Company did not have any assets or liabilities categorized as Level 1 or 2 as of June 30, 2025.

The change in fair value of the Common Warrants (issued in February 2024), the Series A Warrants (issued in February 2022) and the Private Common Warrants (issued in February 2024) for the three-month period ended June 30, 2025, is summarized as follows:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | <br>**Common**<br>**Warrants** | <br>**Series A**<br>**Warrants** | **Series A**<br>**Warrants-**<br>**modified** | **Private**<br>**Common**<br>**Warrants** | <br><br>**Totals** |
| Fair value at April 1, 2025 | $1000 | $140 | 430 | 6000 | $7570 |
| &nbsp;&nbsp;Change in fair value | (900) | (130) | (380) | (5000) | (6410) |
| Fair Value at June 30, 2025 | $100 | $10 | $50 | $1000 | $1160 |

---

The change in fair value of the Common Warrants, the Series A Warrants and the Private Common Warrants for the nine-month period ended June 30, 2025 is summarized as follows:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | <br>**Common**<br>**Warrants** | <br>**Series A**<br>**Warrants** | **Series A**<br>**Warrants-**<br>**modified** | **Private**<br>**Common**<br>**Warrants** | <br><br>**Totals** |
| Fair value at October 1, 2024 | $27000 | $15000 | $16000 | $262000 | $320000 |
| &nbsp;&nbsp;Change in fair value | (26900) | (14990) | (15950) | (261000) | (318840) |
| Fair Value at June 30, 2025 | $100 | $10 | $50 | $1000 | $1160 |

---

[**Table of Contents**](#TOC)

**APPLIED DNA SCIENCES, INC. AND SUBSIDIARIES**

**FOOTNOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**JUNE 30, 2025**

**(unaudited)**

**NOTE J – DISCONTINUED OPERATIONS**

On June 27, 2025, the Company implemented a strategic restructuring and realignment of resources to focus exclusively on its Therapeutic DNA Production Services business. As part of actions undertaken, the Company implemented a workforce reduction of approximately 27% of its then current headcount and has ceased operations at ADCL.

The Company's actions are intended to reduce its operating costs and concentrate resources on the development and commercialization of its Therapeutic DNA Production Services business. The Company expects to pay approximately three hundred thousand dollars ($300,000) in one-time charges related to the June 30, 2025, workforce reduction and ceasing of operations at ADCL, primarily for separation benefits. As a result of this restructuring, the operations and financial results of ADCL have been accounted for as discontinued operations.

The following table presents the major classes of ADCL's results within Net loss from discontinued operations, net of tax in the condensed consolidated statement of operations:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three months Ended June 30,** | **Three months Ended June 30,** | **Nine months Ended June 30,** | **Nine months Ended June 30,** |
|  | **2025** | **2024** | **2025** | **2024** |
| &nbsp;&nbsp;Clinical laboratory service revenues | $26050 | $324730 | $572928 | $992450 |
| &nbsp;&nbsp;Cost of clinical laboratory service revenues | 301556 | 322098 | 795237 | $993299 |
| Gross profit | (275506) | 2632 | (222309) | (849) |
| Selling, general and administrative | 69478 | 43031 | 192877 | 322530 |
| Interest (Income) | (25) | (6608) | (3302) | (50982) |
| Other (income), net | (8764) |  | (8764) |  |
| Net loss from discontinued operations | (336195) | (33791) | (403120) | (272397) |
| Provision for income taxes |  |  |  |  |
| Net loss from discontinued operations, net of tax | $(336195) | $(33791) | $(403120) | $(272397) |

---

Assets and liabilities of discontinued operations associated with ADCL presented in the condensed consolidated balance sheet as of June 30, 2025 and September 30, 2024 are included in the following table:

---

| | | |
|:---|:---|:---|
|  | **June 30,** | **September 30,** |
|  | **2025** | **2024** |
| **ASSETS** |  |  |
| Cash and cash equivalents | $12458 | $578732 |
| Accounts receivable, net | 12550 | 33760 |
| Inventories |  | 5867 |
| Prepaid expenses and other current assets |  | 59787 |
| Total current assets of discontinued operations | 25008 | 678146 |
| Property and equipment, net | 11264 | 94337 |
| Total assets of discontinued operations | 36272 | 772483 |
| **LIABILITIES** |  |  |
| Accounts payable and accrued liabilities | 124565 | 56061 |
| Total liabilities of discontinued operations | $124565 | $56061 |

---

[**Table of Contents**](#TOC)

#### Item 2. — Management's Discussion and Analysis of Financial Condition and Results of Operations.

#### Forward-Looking Statements

Forward-looking statements can generally be identified by the fact that they do not relate strictly to historical or current facts and include, but are not limited to, statements using terminology such as "can", "may", "could", "should", "assume", "forecasts", "believe", "designed to", "will", "expect", "plan", "anticipate", "estimate", "potential", "position", "predicts", "strategy", "guidance", "intend", "budget", "seek", "project" or "continue", or the negative thereof or other comparable terminology regarding beliefs, plans, expectations or intentions regarding the future. You should read statements that contain these words carefully because they:

● discuss our future expectations;

● contain projections of our future results of operations or of our financial condition; and

● state other "forward-looking" information.

We believe it is important to communicate our expectations. However, forward-looking statements are based on our current expectations, assumptions, estimates and projections about our business and our industry and are subject to known and unknown risks, uncertainties and other factors. Accordingly, our actual results and the timing of certain events may differ materially from those expressed or implied in such forward-looking statements due to a variety of factors and risks, including, but not limited to, those set forth in this Item 2, "Management's Discussion and Analysis of Financial Condition and Results of Operations" and in our unaudited condensed consolidated financial statements and notes thereto included in this Quarterly Report, those set forth from time to time in our other filings with the SEC, including our Annual Report on Form 10-K for the fiscal year ended September 30, 2024, and the following factors and risks:

● our expectations of future revenues, expenditures, capital or other funding requirements;

● the adequacy of our cash and working capital to fund present and planned operations and growth;

● the substantial doubt relating to our ability to continue as a going concern;

● our need for additional financing which may in turn require the issuance of additional shares of common stock, preferred stock or other debt or equity securities (including convertible securities) which would dilute the ownership held by stockholders;

● our identification of a material weakness in our internal control over financial reporting;

● our business strategy, including our concentration on Therapeutic DNA Production Services, which is unproven and for which demand may not materialize;

● the timing of our expansion plans, including the development of new production facilities for our nucleic-acid production solutions;

● demand for Therapeutic DNA Production Services;

● our expectations concerning existing or potential development and license agreements for third-party collaborations or joint ventures;

[**Table of Contents**](#TOC)

● regulatory approval and compliance for our Therapeutic DNA Production Services, upon which our business strategy is substantially dependent;

● the effect of governmental regulations generally;

● our expectations of when regulatory submissions may be filed or when regulatory approvals may be received;

● our expectations concerning restructuring of our business model with an emphasis on Therapeutic DNA Production Services;

● our expectations of when or if we will become profitable;

● the risk that our stockholders may suffer substantial dilution if certain provisions of our outstanding warrants are utilized;

● the 2025 Reverse Stock Splits may decrease the liquidity of the shares of our common stock and the resulting market price of our common stock may not attract or satisfy the investing requirements of new investors, including institutional investors;

● the risk that our common stock may be delisted from Nasdaq if we fail to comply with the Bid Price Rule or with any other listing requirements of The Nasdaq Capital Market;

● the risk that any stock splits we may implement in the future may decrease our liquidity and the price of our common stock;

● the potential impact of amended Nasdaq Listing Rules 5810 and 5815, which may in certain circumstances prevent the Company from utilizing reverse stock splits to regain compliance with Nasdaq Listing Rules;

● any impacts from current global, economic, sovereign and political conditions and uncertainties, including the effects of, and uncertainty regarding new or proposed tariff or trade regulations.

Any or all of our forward-looking statements may turn out to be wrong. They may be affected by inaccurate assumptions that we might make or by known or unknown risks and uncertainties. Actual outcomes and results may differ materially from what is expressed or implied in our forward-looking statements. Among the factors that could affect future results are:

● the inherent uncertainties of product development based on our new and as yet not fully proven technologies;

● the risks and uncertainties regarding the actual effect on humans of seemingly safe and efficacious formulations and treatments when tested clinically;

● the inherent uncertainties of formulations and treatments that utilize our Therapeutic DNA Production Services;

● the inherent uncertainties associated with clinical trials of product candidates, including product candidates that utilize our Therapeutic DNA Production Services;

● the inherent uncertainties associated with the process of obtaining regulatory clearance or approval to market product candidates, including product candidates that utilize our Therapeutic DNA Production Services;

● the inherent uncertainties associated with commercialization of products that have received regulatory clearance or approval, including products that utilize our Therapeutic DNA Production Services;

● economic and industry conditions generally and in our specific markets;

● the volatility of, and decline in, our stock price; and

● our ability to obtain the necessary financing to fund our operations and effect our strategic development plan.

[**Table of Contents**](#TOC)

Forward-looking statements may include our plans and objectives for future operations, including plans and objectives relating to our products and our future economic performance, projections, business strategy and timing and likelihood of success. Assumptions relating to the forward-looking statements included in this Quarterly Report involve judgments with respect to, among other things, future economic, competitive and market conditions, future business decisions, regulatory outcomes, safety and efficacy, demand for our products and services, and the time and money required to successfully complete development and commercialization of our technologies, all of which are difficult or impossible to predict accurately and many of which are beyond our control.

Any of the assumptions underlying the forward-looking statements contained in this Quarterly Report could prove inaccurate and, therefore, we cannot assure you that any of the results or events contemplated in any of such forward-looking statements will be realized. Based on the significant uncertainties inherent in these forward-looking statements, the inclusion of any such statement should not be regarded as a representation or as a guarantee by us that our objectives or plans will be achieved, and we caution you against relying on any of the forward looking statements contained herein.

Our trademarks currently used in the United States include Applied DNA Sciences<sup>®</sup>, LineaDNA<sup>TM</sup>, LineaRNAP<sup>TM</sup>, LineaIVT<sup>TM</sup> and LineaRx<sup>TM</sup>. We do not intend our use or display of other companies' trade names or trademarks to imply a relationship with, or endorsement or sponsorship of us by, any other companies. All trademarks, service marks and trade names included in this Quarterly Report on Form 10-Q are the property of the respective owners.

**Introduction**

Applied DNA Sciences is a biotechnology company focused on providing nucleic-acid production solutions for the biopharmaceutical and diagnostics industries. Our technologies enable the rapid and efficient cell-free manufacturing of high-quality DNA and RNA, which are essential components for a new generation of advanced biotherapeutics such as gene therapies, personalized medicine, adoptive cell therapies, and mRNA and DNA-based vaccines, as well as in vitro diagnostic ("IVD") applications.

The Company has developed three distinct and complementary technology solutions:

● LineaDNA™: A proprietary, cell-free DNA production system that uses a large-scale polymerase chain reaction (PCR) process. This technology allows for the rapid and efficient production of high-fidelity synthetic DNA without the use of living cells. The resulting DNA can be used in the manufacturing of various biotherapeutics, serve as the starting material for mRNA therapeutics and vaccines, and as a critical component of IVDs.

● LineaRNAP™: A next-generation RNA polymerase ("RNAP") used to transform DNA into mRNA. Our RNAP is engineered with a patented DNA-binding domain that we believe results in high mRNA yields and reduced double-stranded RNA (dsDNA) contamination, a common problematic byproduct produced during mRNA production.

● LineaIVT™: An integrated system that combines the Company's LineaDNA and LineaRNAP technologies. This innovative solution simplifies the mRNA production workflow resulting in a streamlined production process with fewer impurities than traditional methods.

We believe our technology solutions address significant unmet needs, allowing us and our customers to produce DNA and RNA biotherapeutics and diagnostic solutions with unmatched quality and speed. Our business strategy is to focus our resources on further development, commercialization, and customer adoption of our three commercial technology solutions within product and therapeutic modalities where our unique business solutions have distinct advantages over legacy technologies.

Specifically, for the biotherapeutic markets we seek to: (i) capitalize on the rapid growth of DNA needed for advanced biotherapeutics generally via LineaDNA to supply synthetic DNA to customers for use in biotherapeutic discovery and manufacturing; and (ii) leverage LineaDNA, LineaRNAP and LineaIVT to specifically capitalize on the near term growing demand for materials used in mRNA-based drug discovery and manufacturing. For the IVD market, we seek to gain additional market adoption for LineaDNA as a component used in the discovery and manufacturing of various diagnostic technologies with a focus on applications requiring chemically modified DNA.

[**Table of Contents**](#TOC)

**LineaDNA**

LineaDNA is our core enabling technology for rapid, efficient, and scalable cell-free manufacture of high-fidelity synthetic DNA sequences used in the manufacturing of a broad range of biotherapeutics. The LineaDNA platform enzymatically produces a linear form of synthetic DNA we call "LineaDNA" that is an alternative to plasmid-based DNA manufacturing technologies that have supplied the DNA used in biotherapeutics for the past 40 years. LineaDNA can be quickly produced in batches ranging from milligram to grams under a variety of controlled manufacturing processes including research use only (RUO), good laboratory practices (GLP) and good manufacturing practices (GMP).

As of the first quarter of calendar year 2025, there were 4,418 gene, cell and RNA therapies in development from preclinical through pre-registration stages, almost all of which use DNA in their manufacturing process. (Source: ASGCT Gene, Cell & RNA Therapy Landscape: Q1 2025 Quarterly Report). Due to what we believe are the LineaDNA's numerous advantages over legacy nucleic DNA manufacturing platforms, we believe this large number of therapies under development represents a substantial market opportunity for LineaDNA to supplant legacy DNA manufacturing as the source of DNA used during manufacturing.

We believe LineaDNA holds several important advantages over existing cell-based plasmid DNA manufacturing platforms. Plasmid-based DNA manufacturing is based on the complex, costly and time-consuming biological process of amplifying DNA in living bacterial cells. Once amplified, the DNA must be separated from the living cells and other process contaminants via multiple rounds of purification, adding further complexity and costs. Unlike plasmid-based DNA manufacturing, LineaDNA does not require living cells and instead amplifies DNA via the exponential enzymatic process of PCR. The LineaDNA platform is simple, scalable and can rapidly produce large quantities of DNA with minimal purification steps.

We believe the key advantages of LineaDNA include:

● Speed – Production of LineaDNA can be measured in terms of hours, not days and weeks as is the case with plasmid-based DNA manufacturing platforms.

● Scalability – LineaDNA production takes place on efficient bench-top instruments with proprietary processes, allowing for rapid scalability in a minimal footprint resulting in reduced capital expenditure requirements.

● Purity – LineaDNA produced via PCR is pure, resulting in large quantities of only the target DNA sequence. Unwanted DNA sequences such as the plasmid backbone and antibiotic resistance genes, inherent to plasmid DNA, are not present in LineaDNA. In addition, we believe utilizing PCR removes common safety risks associated with plasmid DNA such as endotoxin and host cell genomic and protein contamination.

● Simplicity – The production of LineaDNA is streamlined relative to plasmid-based DNA production. LineaDNA requires only four primary ingredients, does not require living cells or complex fermentation systems and does not require multiple rounds of purification.

● Flexibility – LineaDNA can be easily chemically modified to suit specific customer applications and provides for different physical forms of DNA such as the production of single stranded DNA (ssDNA) and circular double-stranded DNA (cirDNA). In addition, LineaDNA can produce a wide range of complex DNA sequences that are difficult to produce via plasmid-based DNA production platforms. These complex sequences include, without limitation, inverted terminal repeats and long homopolymers such as polyadenylation sequences (poly (A) tail) important for gene therapy and mRNA therapies, respectively.

Preclinical studies conducted by the Company have shown that LineaDNA is substitutable for plasmid DNA in numerous biotherapeutic applications, including:

● DNA vaccines;

● DNA templates to produce RNA, including mRNA therapeutics;

● adoptive cell therapy (CAR-T) manufacturing; and

● homology-directed repair (HDR)-mediated gene editing.

[**Table of Contents**](#TOC)

Further, we believe that LineaDNA is also substitutable for plasmid DNA in the following nucleic acid-based therapies:

● viral vector manufacturing for in vivo and ex vivo gene editing;

● clustered regularly interspaced short palindromic repeats-mediated gene therapy (CRISPR); and

● non-viral gene therapy.

***LineaRNAP***

The number of mRNA therapies under development is growing at a rapid rate, triggered in part by the success of the mRNA COVID-19 vaccines and the recent clinical success of personalized cancer therapeutics. As of the third quarter of calendar 2024, there were over 450 mRNA therapies under development, with the majority of these therapies (65%) in the preclinical stage (Source: ASGCT Gene, Cell & RNA Therapy Landscape: Q1 2025 Quarterly Report). The Company believes that the mRNA market is in a nascent stage that represents a large growth opportunity for the Company via the production and supply of our next-generation LineaRNAP to produce mRNA therapies from DNA templates.

mRNA therapeutics are produced via a process called in vitro transcription ("IVT") that requires a DNA template and RNAP as starting materials. Typically, the RNAP is derived from the T7 bacteriophage ("WT-T7"). LineaRNAP is a patented next generation WT-T7-based RNAP engineered with a proprietary DNA-binding domain resulting we believe in high mRNA yields, increased mRNA integrity and reduced double-stranded RNA (dsDNA) contamination as compared to conventional WT-T7. LineaRNAP is engineered for use either as a direct replacement for WT-T7 in conventional IVT workflows or with chemically modified LineaDNA templates and a proprietary reaction buffer, the latter marketed as our LineaIVT platform.

Company data shows that when used in conventional IVT systems (either using synthetic DNA or plasmid DNA templates), LineaRNAP results in higher mRNA yields, lower dsRNA contamination and higher mRNA integrity when compared to WT-T7. The Company seeks to commercialize LineaRNAP as a standalone product sold to third parties for use in mRNA production workflows that use either synthetic or plasmid DNA templates.

LineaRNAP is produced for the Company under an ISO 13485 quality system by Alphazyme, LLC ("Alphazyme"), a third-party Contract Development and Manufacturing Organization ("CDMO") located in the United States, which the Company believes is sufficient for early-stage clinical use of the enzyme. In conjunction with Alphazyme, the Company completed manufacturing process development work on its LineaRNAP to increase the production scale of the enzyme and reduce unit costs. The Company believes current manufacturing capacity for LineaRNAP provided by Alphazyme is sufficient to meet near term needs.

**LineaIVT**

LineaIVT is an innovative integrated system for mRNA manufacturing input materials that combines: (i) the Company's chemically modified LineaDNA IVT templates; (ii) LineaRNAP; and (iii) a proprietary IVT reaction buffer to simplify mRNA workflows and reduce dsRNA.

The LineaIVT platform leverages our patented LineaRNAP's DNA binding domain to chemically bind to chemically modified LineaDNA IVT templates, enabling the use of a proprietary IVT reaction buffer. Internal data shows that the LineaIVT system can reduce dsRNA contamination between 10x and 50x as compared to conventional system for the manufacture of mRNA while achieving equivalent or greater target mRNA yields.

We believe the key advantages of the LineaIVT platform include:

● The reduction of dsRNA contamination resulting in higher target mRNA yields with the potential to reduce downstream processing steps. dsRNA is a problematic immunogenic byproduct produced during conventional mRNA manufacture;

● delivery of LineaDNA IVT templates in as little as 14 days for milligram scale and 30 days for gram scale;

● reduced manufacturing complexities through single sourcing and potentially reduced mRNA purification requirement to meet target quality standards; and

[**Table of Contents**](#TOC)

● potentially enabling mRNA manufacturers to produce mRNA drug substance in less than 45 days.

***Manufacturing Scale-up***

The Company offers or plans to offer several quality grades of LineaDNA, each of which will have different permitted uses.

---

| | | |
|:---|:---|:---|
| **LineaDNA Quality Grade** | **Permitted Use** | **Company Status** |
| RUO | Research and pre-clinical discovery | Currently available |
| GMP for Starting Materials | DNA critical starting materials for the production of mRNA therapies | Currently available |
| GMP for Drug Substance | DNA biologic, drug substance and/or drug product | Planned availability in 2H CY 2026  |

---

We currently manufacture LineaDNA pursuant to GLP and in January 2025 completed the buildout of a fit for purpose manufacturing facility within our current Stony Brook, NY facility capable of producing LineaDNA IVT templates under GMP suitable for use as a critical starting material for clinical and commercial mRNA therapeutics and vaccines.

As of February 2026, the FDA has announced harmonization of GMP requirements with ISO 13485 quality standards. We are currently pursuing ISO 13485 certification, which is expected to be completed in FY2026 Q1.

Our current GMP manufacturing site can produce up to 10 grams of LineaDNA DNA annually, running at single shift capacity. In addition, the Company has additional annual manufacturing capacity for RUO LineaDNA of more than 15 grams per year. We believe our current manufacturing capabilities are sufficient to support near-term customer demand.

In addition, we believe our GMP manufacturing site can support LineaDNA manufactured under GMP suitable for use as, or incorporation into, a biologic, drug substance and/or drug product, which we currently expect to be available during the second half of calendar year 2026. Drug substances are the pharmaceutically active components of drug products.

The Company also plans to offer several quality grades of LineaRNAP, each of which will have different permitted uses. Currently, all manufacturing of LineaRNAP is performed by a CDMO (Alphazyme, LLC):

---

| | | |
|:---|:---|:---|
| **LineaRNAP Quality Grade** | **Permitted Use** | **Company Status** |
| RUO | Research and pre-clinical discovery | Currently available |
| GMP Suitable for Early Clinical Trials | Use to make mRNA used for IND-enabling studies and early-stage clinical trials | Currently available under ISO 13485 QMS |
| GMP | Use to manufacture mRNA used in late-stage clinical trials and commercial manufacturing | Planned availability in 2H CY2026 |

---

The Company plans to work with its current enzyme manufacturer CDMO (Alphazyme, LLC) or other third-party manufacturers to continue to reduce manufacturing unit costs. In addition, and based on customer demand, the Company plans to explore full GMP manufacturing of LineaRNAP with its current or other third-party CDMOs during FY2026, with planned availability in 2H CY2026.

**Segment Business Strategy**

We believe our technology solutions are differentiated in the market and offer compelling commercial advantages over legacy technologies. We seek to leverage our technology solutions to gain market share for our nucleic acid (both DNA and mRNA) production solutions.

Our business strategy relating to the biotherapeutics market is twofold: (i) to capitalize on the rapid growth of biotherapeutics requiring DNA generally via our LineaDNA platform to supply synthetic DNA to customers for use in biotherapeutic discovery and manufacturing; and (ii) to leverage LineaDNA, LineaRNAP and LineaIVT to specifically capitalize on the near term growing demand for input materials used in mRNA-based drug discovery and manufacturing.

[**Table of Contents**](#TOC)

In addition, we seek to capitalize on the growing demand within the IVD sector for chemically modified and/or linear synthetic DNA as a component used in the development manufacture of diagnostic technologies. We believe demand for this market is evidenced by the Company's existing multi-year, multi-order contract with a global IVD manufacturer.

Currently we offer fee-for-service manufacturing under our technology solutions. In the future, we may consider exploring technology out-licensing models for some or all of our technology solutions. In addition, we seek to strike collaborations both upstream and downstream of our technology solutions within the biotherapeutic manufacturing marketplace. Examples of downstream collaborations may include, without limitation, de novo synthesis of long DNA sequences or shorter DNA oligonucleotides. Examples of upstream collaborations may include CDMOs manufacturing biotherapeutic products and/or drug substances, including without limitation mRNA.

**Comparison of Results of Operations for the Three -Month Periods Ended June 30, 2025 and 2024**

**Revenues**

***Product revenues***

For the three-month periods ended June 30, 2025 and 2024, we generated $195,262 and $246,644 in revenues from product sales, respectively. Product revenues decreased by $51,382 or 21% for the three-month period ended June 30, 2025 as compared to the three-month period ended June 30, 2024. The decrease in product revenues was primarily related to a decrease of approximately $58,000 due to the timing of orders from our large-scale DNA manufacturing business within our Therapeutic DNA Production Services segment.

***Service Revenues***

For the three-month periods ended June 30, 2025 and 2024, we generated $109,131 and $226,145 in revenues from sales of services, respectively. The decrease in service revenues of $117,014 or 52% for the three-month period ended June 30, 2025, as compared to the same period in the prior fiscal year is attributable to a decrease within our DNA Tagging and Security Products and Services segment related to a decline in our textile isotopic testing services, due to the wind down of our tagging business.

**Cost and Expenses**

***Gross Profit***

Gross profit for the three-month period ended June 30, 2025, decreased by $237,471 or 98% from $242,601 for the three-month period ended June 30, 2024 to $5,130. The gross profit percentage was 2% and 51% for the three-month periods ended June 30, 2025 and 2024, respectively. The decline in gross profit percentage was primarily the result of lower product and service revenue during the current period, as compared to the same period in the prior fiscal year. The higher volume of both product and service revenues in the prior period was able to better absorb the fixed costs that are included in cost of product revenues.

#### Selling, General and Administrative
Selling, general and administrative expenses for the three-month period ended June 30, 2025 increased by $294,764 or 11% to $2,930,627 as compared to $2,635,863 for the three-month period ended June 30, 2024. The increase is primarily attributable to an increase in salaries and wages for the accrual of $450,000 related to the separation agreement with the former CEO. This increase was offset by decreases in professional fees of approximately $47,000, primarily for a reduction in accounting fees, as well as a decrease in investor relation and D&O insurance expenses of approximately $42,000 and 23,000, respectively. Consulting expense also declined by approximately $30,000.

#### Research and Development
Research and development expenses decreased to $768,563 for the three-month period ended June 30, 2025 from $913,031 for the three-month period ended June 30, 2024, a decrease of $144,468 or 16%. This decrease was attributable to decreased payroll charges of approximately $134,000, as well as a decrease in laboratory supplies of $135,000 for the development of an enzyme during the prior year period. These decreases were offset by an increase in consulting expense of $82,000 related to a development project during the three-month period ended June 30, 2025.

[**Table of Contents**](#TOC)

#### Interest income
Interest income for the three-month period ended June 30, 2025 increased $10,549 or 36% to $40,237 as compared to $29,688 in the three-month period ended June 30, 2024 due to interest earned on our money market accounts.

***Unrealized gain on change in fair value of warrants classified as a liability***

Unrealized gain on change in fair value of warrants classified as a liability for the three-month periods ended June 30, 2025 and 2024 was $6,410 and $5,160,000, respectively, which relates to the change in fair value of the warrants that are classified as a liability. The primary driver of the change is the decrease in our stock price.

***Other expense, net***

Other expense, net for the three-month periods ended June 30, 2025 and 2024, was $531 and $103, respectively.

***Loss from operations***

Loss from operations increased $387,767, or 12% to $3,694,060 for the three-month period ended June 30, 2025 compared to $3,306,293 for the three-month period ended June 30, 2024 due to the factors noted above.

**Comparison of Results of Operations for the Nine-Month Periods Ended June 30, 2025 and 2024**

**Revenues**

***Product revenues***

For the nine-month periods ended June 30, 2025 and 2024, we generated $1,239,747 and $947,086 in revenues from product sales, respectively. Product revenue increased by $292,661 or 31% for the nine-month period ended June 30, 2025 as compared to the same period in the prior fiscal year. The increase in product revenues was primarily within our Therapeutic DNA Production Services segment for an increase in shipments for our large-scale DNA manufacturing business of approximately $191,000, as well as a net increase of approximately $100,000 within our DNA Tagging and Security Products and Services segment primarily attributable to an increase of approximately $230,000 year over year in cotton DNA tagging revenue, offset by a decrease of approximately $87,000 in sales to a nutraceutical customer.

***Service revenues***

For the nine-month periods ended June 30, 2025 and 2024 we generated $697,759 and $678,777 in revenues from sales of services, respectively. The increase in service revenues of $18,982 or 3% for the nine-month period ended June 30, 2025, as compared to the same period in the prior fiscal year is attributable to increases of approximately $83,000 for isotopic testing services for textiles within our DNA Tagging and Security Products and Services segment, offset primarily by a decrease of approximately $43,000 related to research and development projects within our Therapeutic DNA Production Services segment.

**Cost and Expenses**

***Gross Profit***

Gross profit for the nine-month period ended June 30, 2025, increased by $234,058 or 30% from $772,829 for the nine-month period ended June 30, 2024 to $1,006,887. The gross profit percentage was 52% and 48% for the nine-month periods ended June 30, 2025 and 2024, respectively. The increase in gross profit percentage was primarily the result of higher product revenues during the nine-month period ended June 30, 2025 as compared to the same period in the prior fiscal year. The higher volume of product revenues in the current period was able to better absorb the fixed costs that are included in cost of product revenues. To a lesser extent, the improved gross profit percentage was due to product mix, as during the nine-months ended June 30, 2025, the majority of our product revenue was for the shipment of DNA for cotton tagging within our DNA Tagging and Security Products and Services segment, which is at a higher gross margin compared to the product sales during the same period in the prior fiscal year.

[**Table of Contents**](#TOC)

***Selling, General and Administrative***

Selling, general and administrative expenses remained consistent at $8,423,602 and $8,440,919 for the nine-month periods ended June, 2025 and 2024, respectively.

***Research and Development***

Research and development expenses decreased to $2,632,931 for the nine-month period ended June 30, 2025 from $2,762,040 for the nine-month period ended June 30, 2024, a decrease of $129,109 or 5%. This decrease was attributable to decreased payroll charges of $236,000 offset by an increase in laboratory supplies of approximately $298,000 for the development of an enzyme within our Therapeutic DNA Production Services segment.

***Interest income***

Interest income for the nine-month period ended June 30, 2025 increased $134,773 or 397% to $168,762 as compared to $33,989 in the nine-month period ended June 30, 2024 due to interest earned on our money market accounts, which had higher cash balances during the current period, coupled with higher interest rates.

***Transaction costs allocated to warrant liabilities***

Transaction cost allocated to warrant liabilities for the nine-month period ended June 30, 2024 was $633,198. These transaction costs represent the closing costs from the February 2024 financing transaction. These costs were expensed as it would have resulted in negative additional paid in capital.

***Unrealized gain on change in fair value of warrants classified as a liability***

Unrealized gain on change in fair value of the warrants classified as a liability for the nine-month periods ended June 30, 2025 and 2024 was $318,840 and $9,564,000, respectively, and relates to the change in fair value of the warrants that are classified as a liability. The primary driver of the change is the decrease in our stock price.

***Unrealized loss on change in fair value of warrants classified as a liability-warrant modification***

Unrealized loss on change in fair value of warrants classified as a liability-warrant modification of $394,000 for the nine-month period ended June 30, 2024 represents the change in fair value for the modifications made to certain warrants as a result of the February 2024 financing transaction.

***Loss on issuance of warrants***

The loss on issuance of warrants of $1,633,767 for the nine-month period ended June 30, 2024 relates to the February 2024 financing transaction and is the result of the fair value of the warrants being greater than the cash received from the financing.

***Other expense, net***

Other expense, net for the nine-month periods ended June 30, 2025 and 2024, was $23,778 and $9,060, respectively.

***Loss from operations***

Loss from operations decreased $380,484, or 4% from $10,430,130 for the nine-month period ended June 30, 2024 compared to $10,049,646 for the nine-month period ended June 30, 2025 due to the factors noted above.

**Liquidity and Capital Resources**

Our liquidity needs consist of our working capital requirements and research and development expenditure funding. As of June 30, 2025, we had working capital of $3,692,499, which excludes current assets and current liabilities of discontinued operations. For the nine-month period ended June 30, 2025, we used cash in operating activities of $9,141,688 consisting primarily of our loss of $9,585,822 net with non-cash adjustments of $255,601 in depreciation and amortization charges, $318,840 in unrealized gain on change in fair value

[**Table of Contents**](#TOC)

of warrants classified as a liability, $5,212 in write-off of property and equipment, and $80,373 in stock-based compensation expense. Additionally, we had a net increase in operating assets of $545,522 and a net decrease in operating liabilities of $129,157. At June 30, 2025, we had cash and cash equivalents of $4,727,677.

We have recurring net losses. We incurred a net loss from continuing operations of $9,585,822 and generated negative operating cash flow of $9,141,688 for the nine-month period ended June 30, 2025. These factors raise substantial doubt about our ability to continue as a going concern for one year from the issuance of these financial statements. The ability of the Company to continue as a going concern is dependent on our ability to further implement our business plan, raise capital, and generate revenues. The financial statements do not include any adjustments that might be necessary if we are unable to continue as a going concern.

Our current capital resources include cash and cash equivalents, accounts receivable and inventories. Historically, we have financed our operations principally from the sale of equity and equity-linked securities.

As discussed in Note E to our condensed consolidated financial statements, on October 31, 2024, we closed on a registered direct offering and received net proceeds, after deducting placement agent fees and other offering expenses payable by us, of approximately $5.7 million. We also received proceeds from the exercise of warrants of $2,220,459 during the nine months ended June 30, 2025 and $292,305 in proceeds from warrant exercises subsequent to June 30, 2025.

As detailed in Note A in our condensed consolidated financial statements, as a result of the strategic restructurings that occurred during January and June 2025, the Company completed a workforce reduction that reduced headcount by a total of 39% for a projected 31% total reduction in payroll expenses as compared to the fiscal year ended September 30, 2024. The projected annual payroll savings is expected to be partially offset by approximately three hundred thousand dollars ($300,000) in one-time charges related to the June 30, 2025 workforce reduction.

***Critical Accounting Estimates and Policies***

Financial Reporting Release No. 60, published by the SEC, recommends that all companies include a discussion of critical accounting policies used in the preparation of their financial statements. While all these significant accounting policies impact our financial condition and results of operations, we view certain of these policies as critical. Policies determined to be critical are those policies that have the most significant impact on our consolidated financial statements and require management to use a greater degree of judgment and estimates. Actual results may differ from those estimates.

We believe that given current facts and circumstances, it is unlikely that applying any other reasonable judgments or estimate methodologies would cause a material effect on our condensed consolidated results of operations, financial position or liquidity for the periods presented in this report.

The accounting policies identified as critical are as follows:

● Revenue recognition; and

● Warrant Liabilities.

***Critical Accounting Estimates***

The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Management bases its estimates on historical experience and on various assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. The most critical estimates include recoverability of long-lived assets, including the values assigned to intangible assets, fair value calculations for warrants, and contingencies. Management reviews its estimates on a regular basis and the effects of any material revisions are reflected in the consolidated financial statements in the period they are deemed necessary. Accordingly, actual results could differ from those estimates.

***Revenue Recognition***

We follow FASB issued accounting standard updates which clarify the principles for recognizing revenue arising from contracts with customers ("ASC 606" or "Topic 606").

[**Table of Contents**](#TOC)

The Company measures revenue at the amounts that reflect the consideration to which it is expected to be entitled in exchange for transferring control of goods and services to customers. The Company recognizes revenue either at the point in time or over the period of time that performance obligations to customers are satisfied. The Company's contracts with customers may include multiple performance obligations (e.g. DNA products, maintenance, authentication services, research and development services, etc.). For such arrangements, the Company allocates revenues to each performance obligation based on their relative standalone selling price.

Due to the short-term nature of the Company's current contracts with customers, it has elected to apply the practical expedients under Topic 606 to: (1) expense as incurred, incremental costs of obtaining a contract and (2) not adjust the consideration for the effects of a significant financing component for contracts with an original expected duration of one year or less.

*Product Revenues*

The Company's DNA product revenues are accounted for/recognized in accordance with contracts with customers. The Company recognizes revenue upon satisfying its promises to transfer goods or services to customers under the terms of its contracts. These performance obligations are satisfied at the point in time the Company transfers control of the goods to the customer, which in nearly all cases is when title to and risk of loss of the goods transfer to the customer. The timing of transfer of title and risk of loss is dictated by customary or explicitly stated contract terms. The Company invoices customers upon shipment, and its collection terms range, on average, from 30 to 60 days.

*Authentication Services*

The Company recognizes revenue from authentication services upon satisfying its promises to provide services to customers under the terms of its contracts. These performance obligations are satisfied at the point in time the Company services are complete, which in nearly all cases is when the authentication report is released to the customer.

*Research and Development Services*

The Company's revenue from its research and development contracts are accounted for/recognized when the performance obligations per the contract are satisfied. These performance obligations are satisfied at the point in time, either when the Company's services are complete, or when the Company transfers control of the goods to the customer, which in nearly all cases is when title to and risk of loss of the goods transfer to the customer, or when a report is released to a customer. The timing of transfer of title and risk of loss is dictated by customary or explicitly stated contract terms. The Company invoices customers upon shipment, or completion of the services and its collection terms range, on average, from 30 to 60 days.

***Warrant Liabilities***

The Company evaluates its issued warrants in accordance with ASC 480 "Distinguishing Liabilities from Equity" and ASC 815-40, "Derivatives and Hedging — Contracts in Entity's Own Equity" and concluded that due to the terms of certain of its warrant agreements, the instruments do not qualify for equity treatment. As such, the Common Warrants, Series A Warrants and Private Common Warrants were recorded as a liability on the consolidated balance sheet and measured at fair value at inception and at each reporting date in accordance with ASC 820, "Fair Value Measurement", with changes in fair value recognized in the condensed consolidated statement of operations in the period of change.

**Off-Balance Sheet Arrangements**

As a requirement of our lease agreement for our corporate headquarters entered into during January 2023, in lieu of security deposit, we provided a standby letter of credit of $750,000. The letter of credit is effective through January 2026.

**Inflation**

The effect of inflation on our revenue and operating results was not significant.

#### Item 3 . — Quantitative and Qualitative Disclosures About Market Risk .
Information requested by this Item is not applicable as we are electing scaled disclosure requirements available to smaller reporting companies with respect to this Item.

[**Table of Contents**](#TOC)

#### Item 4. — Controls and Procedures .
***Evaluation of Disclosure Controls and Procedures***

As of the end of the period covered by this Quarterly Report on Form 10-Q, we conducted an evaluation, under the supervision of and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act). Disclosure controls and procedures are those controls and procedures designed to provide reasonable assurance that the information required to be disclosed in our Exchange Act filings is (1) recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms, and (2) accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of June 30, 2025, our disclosure controls and procedures were not effective because of a material weakness in our internal control over financial reporting as of June 30, 2025. The material weakness is further described below.

*Material Weakness in Internal Control Over Financial Reporting*

In connection with the review of our condensed consolidated financial statements for the nine-month period ended March 31, 2025, we identified a material weakness in our internal control over financial reporting. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis. For the nine-month period ended June 30, 2025, the material weakness related to the controls around the preparation and review of the inputs utilized in fair value calculations, specifically as it related to warrant modifications. Nonetheless, we have concluded that this material weakness does not require a restatement of or change in our consolidated financial statements for any prior interim period. We also developed a remediation plan for this material weakness which is described below.

*Remediation of Material Weakness*

We are committed to maintaining a strong internal control environment and implementing measures designed to help ensure that this material weakness is remediated as soon as possible. To remediate this material weakness, we have implemented controls to ensure that all inputs in our fair value calculations agree to the underlying documents and are properly reviewed. We will consider the material weakness remediated after the applicable controls operate for a sufficient period of time, and management has concluded, through testing, that the controls are operating effectively.

***Changes in Internal Control over Financial Reporting***

During the fiscal quarter ended June 30, 2025, other than the plan discussed above under "Remediation of Material Weakness," there were no changes in our internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

[**Table of Contents**](#TOC)

**Part II - Other Information**

#### Item 1. — Legal Proceedings.
None.

#### Item 1A. — Risk Factors.
In addition to the other information set forth in this report, you should carefully consider the factors discussed in Part I, Item 1A, "Risk Factors" in our Annual Report on Form 10-K of the Company filed with the SEC on December 17, 2024, and as updated and supplemented in subsequent filings. These risk factors could materially harm our business, operating results and financial condition. Additional factors and uncertainties not currently known to us or that we currently consider immaterial also may materially adversely affect our business, financial condition or future results.

**Item 2. — Unregistered Sales of Equity Securities and Use of Proceeds.**

None.

#### Item 3. — Defaults Upon Senior Securities.
None.

#### Item 4. — Mine Safety Disclosures.
Not applicable.

#### Item 5. — Other Information.
None.

[**Table of Contents**](#TOC)

#### Item 6. — Exhibits.

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | | | **Incorporated by Reference to SEC Filing** | **Incorporated by Reference to SEC Filing** | **Incorporated by Reference to SEC Filing** | |
| <br>**Exhibit**<br>**No.** | <br>**Filed Exhibit Description** | <br>**Form** | **Exhibit**<br>**No.** | <br>**File No.** | <br>**Date Filed** | **Filed or Furnished with**<br>**this Form**<br>**10-Q** |
| 3.1 | [Conformed version of Certificate of Incorporation of Applied DNA Sciences, Inc., as most recently amended by the Eighth Certificate of Amendment, effective June 2, 2025](https://www.sec.gov/Archives/edgar/data/744452/000110465925070454/tm2521623d1_ex3-1.htm) | S-8 | 3.1 | 333-2889380 | 07/25/2025 |  |
| 3.2 | [Conformed version of By-Laws, as amended by the Certificate of Amendment to the By-laws, effective November 7, 2024](https://www.sec.gov/Archives/edgar/data/744452/000110465924120259/tm2428625d1_ex3-2.htm) | S-1 | 3.2 | 333-283315 | 11/19/2024 |  |
| 10.1 | [Separation Agreement, dated June 16, 2025, by and between Applied DNA Sciences, Inc. and Dr. James A. Hayward](https://www.sec.gov/Archives/edgar/data/744452/000110465925060258/tm2518240d1_ex10-1.htm) | 8-K | 10.1 | 001-36745 | 06/17/2025 |  |
| 31.1\* | [Certification of Chief Executive Officer, pursuant to Rules 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002](apdn-20250630xex31d1.htm) |  |  |  |  | X |
| 31.2\* | [Certification of Chief Financial Officer, pursuant to Rules 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002](apdn-20250630xex31d2.htm) |  |  |  |  | X |
| 32.1\*\* | [Certification of Chief Executive Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002](apdn-20250630xex32d1.htm) |  |  |  |  | X |
| 32.2\*\* | [Certification of Chief Financial Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002](apdn-20250630xex32d2.htm) |  |  |  |  | X |
| 101 INS\* | Inline XBRL Instance Document |  |  |  |  | X |
| 101 SCH\* | Inline XBRL Taxonomy Extension Schema Document |  |  |  |  | X |
| 101 CAL\* | Inline XBRL Taxonomy Extension Calculation Linkbase Document |  |  |  |  | X |
| 101 DEF\* | Inline XBRL Taxonomy Extension Definition Linkbase Document |  |  |  |  | X |
| 101 LAB\* | Inline XBRL Extension Label Linkbase Document |  |  |  |  | X |
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibits 101) |  |  |  |  | X |

---

\* Filed herewith

\*\* Furnished herewith

Exhibits 32.1 and 32.2 are being furnished and shall not be deemed to be "filed" for purposes of Section 18 of the Exchange Act or otherwise subject to the liability of that section, nor shall such exhibits be deemed to be incorporated by reference in any registration statement or other document filed under the Securities Act or the Exchange Act, except as otherwise stated in any such filing.

[**Table of Contents**](#TOC)

**Signatures**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | |
|:---|:---|
|  | **Applied DNA Sciences, Inc.** |
| Dated: August 14, 2025 | /s/ JUDITH MURRAH |
|  | Judith Murrah |
|  | *Chief Executive Officer* |
|  | *(Duly authorized officer and principal executive officer)* |
|  | /s/ BETH JANTZEN |
| Dated: August 14, 2025 | Beth Jantzen, CPA |
|  | *Chief Financial Officer* |
|  | *(Duly authorized officer and principal financial and accounting officer)* |

---

## Exhibit 31.1

**Exhibit 31.1**

**CERTIFICATION PURSUANT TO RULE 13a-14(a) OR 15d-14(a) OF THE SECURITIES**

**EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE**

**SARBANES-OXLEY ACT OF 2002**

I, Judith Murrah, certify that:

&nbsp;&nbsp;&nbsp;&nbsp;1. I have reviewed this quarterly report on Form 10-Q of Applied DNA Sciences, Inc.;

&nbsp;&nbsp;&nbsp;&nbsp;2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

&nbsp;&nbsp;&nbsp;&nbsp;3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

&nbsp;&nbsp;&nbsp;&nbsp;4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a. designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b. designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c. evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d. disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

&nbsp;&nbsp;&nbsp;&nbsp;5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a. all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b. any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | | |
|:---|:---|:---|
| Dated: August 14, 2025 |  |  |
|  | By: | /s/ JUDITH MURRAH |
|  |  | Judith Murrah |
|  |  | *Chief Executive Officer and Chairperson* |
|  |  | *(Principal Executive Officer)* |

---

------

## Exhibit 31.2

**Exhibit 31.2**

**CERTIFICATION PURSUANT TO RULE 13a-14(a) OR 15d-14(a) OF THE SECURITIES**

**EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE**

**SARBANES-OXLEY ACT OF 2002**

I, Beth Jantzen, certify that:

&nbsp;&nbsp;&nbsp;&nbsp;1. I have reviewed this quarterly report on Form 10-Q of Applied DNA Sciences, Inc.;

&nbsp;&nbsp;&nbsp;&nbsp;2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

&nbsp;&nbsp;&nbsp;&nbsp;3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

&nbsp;&nbsp;&nbsp;&nbsp;4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a. designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b. designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c. evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d. disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

&nbsp;&nbsp;&nbsp;&nbsp;5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a. all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b. any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | | |
|:---|:---|:---|
| Dated: August 14, 2025 |  |  |
|  | By: | /s/ BETH JANTZEN |
|  |  | Beth Jantzen, CPA |
|  |  | *Chief Financial Officer* |
|  |  | *(Principal Financial Officer)* |

---

------

## Exhibit 32.1

**Exhibit 32.1**

**CERTIFICATION PURSUANT TO 18 U.S.C. 1350, AS ADOPTED PURSUANT TO**

**SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

The undersigned, Judith Murrah, Chief Executive Officer of Applied DNA Sciences, Inc. (the "Company"), in connection with the Company's Quarterly Report on Form 10-Q for the period ended June 30, 2025 (the "Report"), as filed with the Securities and Exchange Commission on the date hereof, hereby certifies pursuant to the requirements of 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that

&nbsp;&nbsp;&nbsp;&nbsp;· the Report fully complies with the requirements of Section 13(a) or 15(d), of the Securities Exchange Act of 1934, and

&nbsp;&nbsp;&nbsp;&nbsp;· the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

This certification is being provided pursuant to 18 U.S.C. 1350 and is not to be deemed a part of the Report, nor is it to be deemed to be "filed" for any purpose whatsoever.

---

| |
|:---|
| /s/ JUDITH MURRAH |
| Judith Murrah |
| *Chief Executive Officer and Chairperson* |
| *(Principal Executive Officer)* |
| Dated: August 14, 2025 |

---

------

## Exhibit 32.2

**Exhibit 32.2**

**CERTIFICATION PURSUANT TO 18 U.S.C. 1350, AS ADOPTED PURSUANT TO**

**SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

The undersigned, Beth Jantzen, Chief Financial Officer of Applied DNA Sciences, Inc. (the "Company"), in connection with the Company's Quarterly Report on Form 10-Q for the period ended June 30, 2025 (the "Report"), as filed with the Securities and Exchange Commission on the date hereof, hereby certifies pursuant to the requirements of 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that

&nbsp;&nbsp;&nbsp;&nbsp;· the Report fully complies with the requirements of Section 13(a) or 15(d), of the Securities Exchange Act of 1934, and

&nbsp;&nbsp;&nbsp;&nbsp;· the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

This certification is being provided pursuant to 18 U.S.C. 1350 and is not to be deemed a part of the Report, nor is it to be deemed to be "filed" for any purpose whatsoever.

---

| |
|:---|
| /s/ BETH JANTZEN |
| Beth Jantzen, CPA |
| *Chief Financial Officer* |
| *(Principal Financial Officer)* |
| Dated: August 14, 2025 |

---

------